CN1145582A - 含有酸性活性物质的低pH值的水解稳定的化妆品组合物 - Google Patents
含有酸性活性物质的低pH值的水解稳定的化妆品组合物 Download PDFInfo
- Publication number
- CN1145582A CN1145582A CN95192519A CN95192519A CN1145582A CN 1145582 A CN1145582 A CN 1145582A CN 95192519 A CN95192519 A CN 95192519A CN 95192519 A CN95192519 A CN 95192519A CN 1145582 A CN1145582 A CN 1145582A
- Authority
- CN
- China
- Prior art keywords
- mixtures
- group
- ppg
- composition
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002378 acidificating effect Effects 0.000 title claims abstract description 31
- 239000002537 cosmetic Substances 0.000 title abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 169
- -1 hydroxy fatty acids Chemical class 0.000 claims abstract description 51
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000002736 nonionic surfactant Substances 0.000 claims abstract description 22
- 239000004480 active ingredient Substances 0.000 claims abstract description 21
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 19
- 239000002253 acid Substances 0.000 claims abstract description 17
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims abstract description 16
- 150000001298 alcohols Chemical class 0.000 claims abstract description 16
- 239000004094 surface-active agent Substances 0.000 claims abstract description 13
- 125000002091 cationic group Chemical group 0.000 claims abstract description 11
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 11
- 229920005628 alkoxylated polyol Polymers 0.000 claims abstract description 6
- 125000000129 anionic group Chemical group 0.000 claims abstract description 6
- 150000002170 ethers Chemical class 0.000 claims abstract description 6
- 238000002844 melting Methods 0.000 claims abstract description 6
- 230000008018 melting Effects 0.000 claims abstract description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 61
- 239000013543 active substance Substances 0.000 claims description 35
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 32
- 229960004889 salicylic acid Drugs 0.000 claims description 30
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 26
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 claims description 25
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 25
- 125000004432 carbon atom Chemical group C* 0.000 claims description 20
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 19
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 claims description 12
- 229920005862 polyol Chemical group 0.000 claims description 12
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 10
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 claims description 10
- 239000002202 Polyethylene glycol Substances 0.000 claims description 9
- 229960000541 cetyl alcohol Drugs 0.000 claims description 9
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 8
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 claims description 8
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 claims description 8
- 150000003077 polyols Chemical group 0.000 claims description 8
- 229930002330 retinoic acid Natural products 0.000 claims description 8
- 229960001727 tretinoin Drugs 0.000 claims description 8
- ILCOCZBHMDEIAI-UHFFFAOYSA-N 2-(2-octadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCO ILCOCZBHMDEIAI-UHFFFAOYSA-N 0.000 claims description 7
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 claims description 7
- 239000003093 cationic surfactant Substances 0.000 claims description 7
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 claims description 7
- 239000004664 distearyldimethylammonium chloride (DHTDMAC) Substances 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 229940098760 steareth-2 Drugs 0.000 claims description 7
- 229940100458 steareth-21 Drugs 0.000 claims description 7
- ZQCIPRGNRQXXSK-UHFFFAOYSA-N 1-octadecoxypropan-2-ol Chemical compound CCCCCCCCCCCCCCCCCCOCC(C)O ZQCIPRGNRQXXSK-UHFFFAOYSA-N 0.000 claims description 6
- OAAZUWWNSYWWHG-UHFFFAOYSA-N 1-phenoxypropan-1-ol Chemical compound CCC(O)OC1=CC=CC=C1 OAAZUWWNSYWWHG-UHFFFAOYSA-N 0.000 claims description 6
- IBLKWZIFZMJLFL-UHFFFAOYSA-N 1-phenoxypropan-2-ol Chemical compound CC(O)COC1=CC=CC=C1 IBLKWZIFZMJLFL-UHFFFAOYSA-N 0.000 claims description 6
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 6
- 244000060011 Cocos nucifera Species 0.000 claims description 6
- 235000013162 Cocos nucifera Nutrition 0.000 claims description 6
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 6
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims description 6
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 6
- 239000004098 Tetracycline Substances 0.000 claims description 6
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 claims description 6
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 claims description 6
- 229960001680 ibuprofen Drugs 0.000 claims description 6
- 229960002009 naproxen Drugs 0.000 claims description 6
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 6
- 229960005323 phenoxyethanol Drugs 0.000 claims description 6
- 229940106026 phenoxyisopropanol Drugs 0.000 claims description 6
- 229940078491 ppg-15 stearyl ether Drugs 0.000 claims description 6
- 229960002180 tetracycline Drugs 0.000 claims description 6
- 229930101283 tetracycline Natural products 0.000 claims description 6
- 235000019364 tetracycline Nutrition 0.000 claims description 6
- 150000003522 tetracyclines Chemical class 0.000 claims description 6
- 229960002255 azelaic acid Drugs 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 150000002334 glycols Chemical group 0.000 claims description 5
- 229960000890 hydrocortisone Drugs 0.000 claims description 5
- 229950001046 piroctone Drugs 0.000 claims description 5
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 claims description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 230000002040 relaxant effect Effects 0.000 claims description 5
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 4
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 4
- 229940120503 dihydroxyacetone Drugs 0.000 claims description 4
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 claims description 4
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 3
- WLCFKPHMRNPAFZ-UHFFFAOYSA-M didodecyl(dimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCC WLCFKPHMRNPAFZ-UHFFFAOYSA-M 0.000 claims description 3
- ZCPCLAPUXMZUCD-UHFFFAOYSA-M dihexadecyl(dimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCC ZCPCLAPUXMZUCD-UHFFFAOYSA-M 0.000 claims description 3
- RSHHCURRBLAGFA-UHFFFAOYSA-M dimethyl-di(tetradecyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCC RSHHCURRBLAGFA-UHFFFAOYSA-M 0.000 claims description 3
- 229960001755 resorcinol Drugs 0.000 claims description 3
- 150000001450 anions Chemical class 0.000 claims description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 229940096956 ppg-11 stearyl ether Drugs 0.000 claims description 2
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 claims 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 claims 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract description 9
- 239000000194 fatty acid Substances 0.000 abstract description 9
- 229930195729 fatty acid Natural products 0.000 abstract description 9
- 230000036556 skin irritation Effects 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 6
- 230000008021 deposition Effects 0.000 abstract description 5
- 230000035515 penetration Effects 0.000 abstract description 5
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 abstract description 2
- 150000002191 fatty alcohols Chemical class 0.000 abstract 2
- 150000002009 diols Chemical class 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 43
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 23
- 239000004615 ingredient Substances 0.000 description 22
- 239000012071 phase Substances 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 17
- 229920001451 polypropylene glycol Polymers 0.000 description 17
- 239000003995 emulsifying agent Substances 0.000 description 16
- 239000000839 emulsion Substances 0.000 description 15
- 210000000434 stratum corneum Anatomy 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- 235000011187 glycerol Nutrition 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 239000007764 o/w emulsion Substances 0.000 description 9
- 210000002615 epidermis Anatomy 0.000 description 8
- 239000003906 humectant Substances 0.000 description 8
- 239000003760 tallow Substances 0.000 description 8
- 206010040844 Skin exfoliation Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 6
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 6
- 239000004205 dimethyl polysiloxane Substances 0.000 description 6
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 6
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 5
- 102000011782 Keratins Human genes 0.000 description 5
- 108010076876 Keratins Proteins 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 206010040880 Skin irritation Diseases 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 238000000151 deposition Methods 0.000 description 5
- 230000003020 moisturizing effect Effects 0.000 description 5
- 231100000475 skin irritation Toxicity 0.000 description 5
- 230000000475 sunscreen effect Effects 0.000 description 5
- 239000000516 sunscreening agent Substances 0.000 description 5
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 4
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 125000005210 alkyl ammonium group Chemical group 0.000 description 4
- 229940061720 alpha hydroxy acid Drugs 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 4
- 239000003599 detergent Substances 0.000 description 4
- 239000003974 emollient agent Substances 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 230000008016 vaporization Effects 0.000 description 4
- 238000009834 vaporization Methods 0.000 description 4
- LCZVSXRMYJUNFX-UHFFFAOYSA-N 2-[2-(2-hydroxypropoxy)propoxy]propan-1-ol Chemical compound CC(O)COC(C)COC(C)CO LCZVSXRMYJUNFX-UHFFFAOYSA-N 0.000 description 3
- 244000144927 Aloe barbadensis Species 0.000 description 3
- 235000002961 Aloe barbadensis Nutrition 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 3
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000011399 aloe vera Nutrition 0.000 description 3
- 230000003255 anti-acne Effects 0.000 description 3
- GDCXBZMWKSBSJG-UHFFFAOYSA-N azane;4-methylbenzenesulfonic acid Chemical compound [NH4+].CC1=CC=C(S([O-])(=O)=O)C=C1 GDCXBZMWKSBSJG-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 229960002227 clindamycin Drugs 0.000 description 3
- 229940086555 cyclomethicone Drugs 0.000 description 3
- 230000035618 desquamation Effects 0.000 description 3
- 229940008099 dimethicone Drugs 0.000 description 3
- NTLIJZACUWTZFB-UHFFFAOYSA-N dimethyl-[3-(octadecanoylamino)propyl]azanium;2-hydroxypropanoate Chemical compound CC(O)C(O)=O.CCCCCCCCCCCCCCCCCC(=O)NCCCN(C)C NTLIJZACUWTZFB-UHFFFAOYSA-N 0.000 description 3
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 3
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 3
- 230000037336 dry skin Effects 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
- 229940051250 hexylene glycol Drugs 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- 230000003780 keratinization Effects 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000004973 liquid crystal related substance Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- QMDUPVPMPVZZGK-UHFFFAOYSA-N n,n-dimethyloctadecan-1-amine;hydrobromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[NH+](C)C QMDUPVPMPVZZGK-UHFFFAOYSA-N 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229940012831 stearyl alcohol Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- ZPFAVCIQZKRBGF-UHFFFAOYSA-N 1,3,2-dioxathiolane 2,2-dioxide Chemical compound O=S1(=O)OCCO1 ZPFAVCIQZKRBGF-UHFFFAOYSA-N 0.000 description 2
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- IJFXRHURBJZNAO-UHFFFAOYSA-N 3-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1 IJFXRHURBJZNAO-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 108010065839 Capreomycin Proteins 0.000 description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 206010040799 Skin atrophy Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229960004050 aminobenzoic acid Drugs 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001153 anti-wrinkle effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 229960004022 clotrimazole Drugs 0.000 description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- VWTINHYPRWEBQY-UHFFFAOYSA-N denatonium Chemical compound [O-]C(=O)C1=CC=CC=C1.C=1C=CC=CC=1C[N+](CC)(CC)CC(=O)NC1=C(C)C=CC=C1C VWTINHYPRWEBQY-UHFFFAOYSA-N 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- PFKRTWCFCOUBHS-UHFFFAOYSA-N dimethyl(octadecyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[NH+](C)C PFKRTWCFCOUBHS-UHFFFAOYSA-N 0.000 description 2
- LVXUNJWLKCUTNF-UHFFFAOYSA-N dimethyl-[3-(octadecanoylamino)propyl]azanium;chloride Chemical compound Cl.CCCCCCCCCCCCCCCCCC(=O)NCCCN(C)C LVXUNJWLKCUTNF-UHFFFAOYSA-N 0.000 description 2
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
- PGQAXGHQYGXVDC-UHFFFAOYSA-N dodecyl(dimethyl)azanium;chloride Chemical compound Cl.CCCCCCCCCCCCN(C)C PGQAXGHQYGXVDC-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000036074 healthy skin Effects 0.000 description 2
- GFMIDCCZJUXASS-UHFFFAOYSA-N hexane-1,1,6-triol Chemical compound OCCCCCC(O)O GFMIDCCZJUXASS-UHFFFAOYSA-N 0.000 description 2
- VAMFXQBUQXONLZ-UHFFFAOYSA-N icos-1-ene Chemical compound CCCCCCCCCCCCCCCCCCC=C VAMFXQBUQXONLZ-UHFFFAOYSA-N 0.000 description 2
- 239000003410 keratolytic agent Substances 0.000 description 2
- 150000003893 lactate salts Chemical class 0.000 description 2
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 2
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 2
- 229940053050 neomycin sulfate Drugs 0.000 description 2
- 239000012875 nonionic emulsifier Substances 0.000 description 2
- 229940101267 panthenol Drugs 0.000 description 2
- 235000020957 pantothenol Nutrition 0.000 description 2
- 239000011619 pantothenol Substances 0.000 description 2
- 230000037368 penetrate the skin Effects 0.000 description 2
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 2
- 229960004448 pentamidine Drugs 0.000 description 2
- 229960003742 phenol Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 230000005808 skin problem Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 description 1
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 1
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- CIDUJQMULVCIBT-MQDUPKMGSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4-amino-3-[[(2s,3r)-3-amino-6-(aminomethyl)-3,4-dihydro-2h-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](NC)[C@@](C)(O)CO1)O)NCC)[C@H]1OC(CN)=CC[C@H]1N CIDUJQMULVCIBT-MQDUPKMGSA-N 0.000 description 1
- LDQAVQLJHUEMEY-JTQLQIEISA-N (2s)-2-(ethylamino)-3-(4-hydroxyphenyl)propanoic acid Chemical compound CCN[C@H](C(O)=O)CC1=CC=C(O)C=C1 LDQAVQLJHUEMEY-JTQLQIEISA-N 0.000 description 1
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- ZEUUPKVZFKBXPW-TWDWGCDDSA-N (2s,3r,4s,5s,6r)-4-amino-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,5s,6r)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N ZEUUPKVZFKBXPW-TWDWGCDDSA-N 0.000 description 1
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 description 1
- XIYOPDCBBDCGOE-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O XIYOPDCBBDCGOE-IWVLMIASSA-N 0.000 description 1
- VXPSARQTYDZXAO-CCHMMTNSSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O VXPSARQTYDZXAO-CCHMMTNSSA-N 0.000 description 1
- RNIADBXQDMCFEN-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-7-chloro-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=C(Cl)C=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O RNIADBXQDMCFEN-IWVLMIASSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- AFENDNXGAFYKQO-VKHMYHEASA-N (S)-2-hydroxybutyric acid Chemical compound CC[C@H](O)C(O)=O AFENDNXGAFYKQO-VKHMYHEASA-N 0.000 description 1
- ZWVMLYRJXORSEP-UHFFFAOYSA-N 1,2,6-Hexanetriol Chemical compound OCCCCC(O)CO ZWVMLYRJXORSEP-UHFFFAOYSA-N 0.000 description 1
- WMKDZGZVVZOYCO-UHFFFAOYSA-N 1-butoxyperoxybutane Chemical class CCCCOOOCCCC WMKDZGZVVZOYCO-UHFFFAOYSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 1
- SIHSSUWJKIEVGQ-UHFFFAOYSA-N 14-methyl-1-(14-methylpentadecoxy)pentadecane Chemical compound CC(C)CCCCCCCCCCCCCOCCCCCCCCCCCCCC(C)C SIHSSUWJKIEVGQ-UHFFFAOYSA-N 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- AZLWQVJVINEILY-UHFFFAOYSA-N 2-(2-dodecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCOCCOCCO AZLWQVJVINEILY-UHFFFAOYSA-N 0.000 description 1
- QVTWQIWXCYMFQI-CZDSEFAFSA-N 2-[(1r,2r,3s,4r,5r,6s)-3-(diaminomethylideneamino)-4-[(2r,3r,4r,5s)-3-[(2s,3s,4s,5r,6s)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine;trihydrochloride Chemical compound Cl.Cl.Cl.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QVTWQIWXCYMFQI-CZDSEFAFSA-N 0.000 description 1
- FEBUJFMRSBAMES-UHFFFAOYSA-N 2-[(2-{[3,5-dihydroxy-2-(hydroxymethyl)-6-phosphanyloxan-4-yl]oxy}-3,5-dihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-4-yl)oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl phosphinite Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(OC2C(C(OP)C(O)C(CO)O2)O)C(O)C(OC2C(C(CO)OC(P)C2O)O)O1 FEBUJFMRSBAMES-UHFFFAOYSA-N 0.000 description 1
- FKMHSNTVILORFA-UHFFFAOYSA-N 2-[2-(2-dodecoxyethoxy)ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCO FKMHSNTVILORFA-UHFFFAOYSA-N 0.000 description 1
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 1
- OBWBSSIUKXEALB-UHFFFAOYSA-N 2-aminoethanol;2-hydroxypropanamide Chemical compound NCCO.CC(O)C(N)=O OBWBSSIUKXEALB-UHFFFAOYSA-N 0.000 description 1
- OGQYJDHTHFAPRN-UHFFFAOYSA-N 2-fluoro-6-(trifluoromethyl)benzonitrile Chemical compound FC1=CC=CC(C(F)(F)F)=C1C#N OGQYJDHTHFAPRN-UHFFFAOYSA-N 0.000 description 1
- HJGHIUCZKMIOLV-UHFFFAOYSA-N 2-hexanoyloxybenzoic acid Chemical compound CCCCCC(=O)OC1=CC=CC=C1C(O)=O HJGHIUCZKMIOLV-UHFFFAOYSA-N 0.000 description 1
- IXIGWKNBFPKCCD-UHFFFAOYSA-N 2-hydroxy-5-octanoylbenzoic acid Chemical compound CCCCCCCC(=O)C1=CC=C(O)C(C(O)=O)=C1 IXIGWKNBFPKCCD-UHFFFAOYSA-N 0.000 description 1
- IKRKINIKITZMKG-UHFFFAOYSA-N 2-hydroxy-5-octylbenzoic acid Chemical compound CCCCCCCCC1=CC=C(O)C(C(O)=O)=C1 IKRKINIKITZMKG-UHFFFAOYSA-N 0.000 description 1
- VHBSECWYEFJRNV-UHFFFAOYSA-N 2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1O.OC(=O)C1=CC=CC=C1O VHBSECWYEFJRNV-UHFFFAOYSA-N 0.000 description 1
- NYHNVHGFPZAZGA-UHFFFAOYSA-N 2-hydroxyhexanoic acid Chemical compound CCCCC(O)C(O)=O NYHNVHGFPZAZGA-UHFFFAOYSA-N 0.000 description 1
- JRHWHSJDIILJAT-UHFFFAOYSA-N 2-hydroxypentanoic acid Chemical compound CCCC(O)C(O)=O JRHWHSJDIILJAT-UHFFFAOYSA-N 0.000 description 1
- DHCJQRNKEXCLCE-UHFFFAOYSA-N 2-phenoxy-2-phenylpropanoic acid Chemical compound C=1C=CC=CC=1C(C)(C(O)=O)OC1=CC=CC=C1 DHCJQRNKEXCLCE-UHFFFAOYSA-N 0.000 description 1
- ILYSAKHOYBPSPC-UHFFFAOYSA-N 2-phenylbenzoic acid Chemical class OC(=O)C1=CC=CC=C1C1=CC=CC=C1 ILYSAKHOYBPSPC-UHFFFAOYSA-N 0.000 description 1
- TUATYNXRYJTQTQ-BVRBKCERSA-N 3,6-diamino-n-[[(2s,5s,8z,11s,15s)-15-amino-11-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;3,6-diamino-n-[[(2s,5s,8z,11s,15s)-15-a Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CNC(=O)CC(N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1C1NC(=N)NCC1.N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CNC(=O)CC(N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1C1NC(=N)NCC1 TUATYNXRYJTQTQ-BVRBKCERSA-N 0.000 description 1
- YUSUWVHVRUYYHV-UHFFFAOYSA-N 3-(octadecanoylamino)propyl dihydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCCOP(O)(O)=O YUSUWVHVRUYYHV-UHFFFAOYSA-N 0.000 description 1
- RHEFZZHALQVVFD-UHFFFAOYSA-N 3-octadec-9-enoxypropan-1-ol Chemical compound CCCCCCCCC=CCCCCCCCCOCCCO RHEFZZHALQVVFD-UHFFFAOYSA-N 0.000 description 1
- WTJXVDPDEQKTCV-UHFFFAOYSA-N 4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2C1CC1C(N(C)C)C(=O)C(C(N)=O)=C(O)C1(O)C2=O WTJXVDPDEQKTCV-UHFFFAOYSA-N 0.000 description 1
- PTNZGHXUZDHMIQ-UHFFFAOYSA-N 4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2C(C)C(C(O)C3C(C(O)=C(C(N)=O)C(=O)C3N(C)C)(O)C3=O)C3=C(O)C2=C1O PTNZGHXUZDHMIQ-UHFFFAOYSA-N 0.000 description 1
- YWMSSKBMOFPBDM-UHFFFAOYSA-N 4-carbamoylbenzenesulfonyl chloride Chemical compound NC(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 YWMSSKBMOFPBDM-UHFFFAOYSA-N 0.000 description 1
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920013683 Celanese Polymers 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Chemical class 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 241001340526 Chrysoclista linneella Species 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- YAVZHCFFUATPRK-YZPBMOCRSA-N Erythromycin stearate Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 YAVZHCFFUATPRK-YZPBMOCRSA-N 0.000 description 1
- KIWBPDUYBMNFTB-UHFFFAOYSA-N Ethyl hydrogen sulfate Chemical compound CCOS(O)(=O)=O KIWBPDUYBMNFTB-UHFFFAOYSA-N 0.000 description 1
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 241000208680 Hamamelis mollis Species 0.000 description 1
- DKLKMKYDWHYZTD-UHFFFAOYSA-N Hexylcaine Chemical compound C=1C=CC=CC=1C(=O)OC(C)CNC1CCCCC1 DKLKMKYDWHYZTD-UHFFFAOYSA-N 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical class NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229920002884 Laureth 4 Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 229920002305 Schizophyllan Polymers 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- SLPRNVZOANHRIB-UHFFFAOYSA-M [Cl-].C(CCCCCCCCCCCCCCCCC)[N+](C(C)C)(C)CCCCCCCCCCCCCCCC Chemical compound [Cl-].C(CCCCCCCCCCCCCCCCC)[N+](C(C)C)(C)CCCCCCCCCCCCCCCC SLPRNVZOANHRIB-UHFFFAOYSA-M 0.000 description 1
- NBVZMBLJRHUOJR-UHFFFAOYSA-N [amino-[4-[6-[4-[amino(azaniumylidene)methyl]phenoxy]hexoxy]phenyl]methylidene]azanium;2-hydroxyethanesulfonate Chemical compound OCCS(O)(=O)=O.OCCS(O)(=O)=O.C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 NBVZMBLJRHUOJR-UHFFFAOYSA-N 0.000 description 1
- DHFCLYNGVLPKPK-UHFFFAOYSA-N acetamide;2-aminoethanol Chemical compound CC(N)=O.NCCO DHFCLYNGVLPKPK-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229960001656 amikacin sulfate Drugs 0.000 description 1
- 229940051879 analgesics and antipyretics salicylic acid and derivative Drugs 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940111133 antiinflammatory and antirheumatic drug oxicams Drugs 0.000 description 1
- 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- IJTPQQVCKPZIMV-UHFFFAOYSA-N bucloxic acid Chemical compound ClC1=CC(C(=O)CCC(=O)O)=CC=C1C1CCCCC1 IJTPQQVCKPZIMV-UHFFFAOYSA-N 0.000 description 1
- 229950005608 bucloxic acid Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960004602 capreomycin Drugs 0.000 description 1
- 229960002968 capreomycin sulfate Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940105270 carbocaine Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- CZPLANDPABRVHX-UHFFFAOYSA-N cascade blue Chemical compound C=1C2=CC=CC=C2C(NCC)=CC=1C(C=1C=CC(=CC=1)N(CC)CC)=C1C=CC(=[N+](CC)CC)C=C1 CZPLANDPABRVHX-UHFFFAOYSA-N 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- ITVPBBDAZKBMRP-UHFFFAOYSA-N chloro-dioxido-oxo-$l^{5}-phosphane;hydron Chemical compound OP(O)(Cl)=O ITVPBBDAZKBMRP-UHFFFAOYSA-N 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 229960003185 chlortetracycline hydrochloride Drugs 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960001200 clindamycin hydrochloride Drugs 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008271 cosmetic emulsion Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 210000001047 desmosome Anatomy 0.000 description 1
- PFCBRXGBIQWFED-UHFFFAOYSA-N didodecyl(methyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCC[NH+](C)CCCCCCCCCCCC PFCBRXGBIQWFED-UHFFFAOYSA-N 0.000 description 1
- SWWQNNDPJXYCNJ-UHFFFAOYSA-N didodecylazanium;chloride Chemical compound Cl.CCCCCCCCCCCCNCCCCCCCCCCCC SWWQNNDPJXYCNJ-UHFFFAOYSA-N 0.000 description 1
- RNMIVNUNMNQFRD-UHFFFAOYSA-N dihexadecylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[NH2+]CCCCCCCCCCCCCCCC RNMIVNUNMNQFRD-UHFFFAOYSA-N 0.000 description 1
- PRAHCKGOTFKWKD-UHFFFAOYSA-N dimethyl(propyl)azanium;chloride Chemical compound Cl.CCCN(C)C PRAHCKGOTFKWKD-UHFFFAOYSA-N 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- QHNXEVRKFKHMRL-UHFFFAOYSA-N dimethylazanium;acetate Chemical compound CNC.CC(O)=O QHNXEVRKFKHMRL-UHFFFAOYSA-N 0.000 description 1
- KGOGNDXXUVELIQ-UHFFFAOYSA-N dioctadecylazanium;chloride Chemical compound Cl.CCCCCCCCCCCCCCCCCCNCCCCCCCCCCCCCCCCCC KGOGNDXXUVELIQ-UHFFFAOYSA-N 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- VZXFEELLBDNLAL-UHFFFAOYSA-N dodecan-1-amine;hydrobromide Chemical compound [Br-].CCCCCCCCCCCC[NH3+] VZXFEELLBDNLAL-UHFFFAOYSA-N 0.000 description 1
- 150000002028 dodecanols Chemical class 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- DLFDEDJIVYYWTB-UHFFFAOYSA-N dodecyl(dimethyl)azanium;bromide Chemical compound Br.CCCCCCCCCCCCN(C)C DLFDEDJIVYYWTB-UHFFFAOYSA-N 0.000 description 1
- DDXLVDQZPFLQMZ-UHFFFAOYSA-M dodecyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)C DDXLVDQZPFLQMZ-UHFFFAOYSA-M 0.000 description 1
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 1
- XJWSAJYUBXQQDR-UHFFFAOYSA-M dodecyltrimethylammonium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)C XJWSAJYUBXQQDR-UHFFFAOYSA-M 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 229960004082 doxycycline hydrochloride Drugs 0.000 description 1
- 229960000385 dyclonine Drugs 0.000 description 1
- BZEWSEKUUPWQDQ-UHFFFAOYSA-N dyclonine Chemical compound C1=CC(OCCCC)=CC=C1C(=O)CCN1CCCCC1 BZEWSEKUUPWQDQ-UHFFFAOYSA-N 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960004142 erythromycin stearate Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- 229960001618 ethambutol hydrochloride Drugs 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- WBJQGBBEPJLNKP-UHFFFAOYSA-N ethyl-dimethyl-[3-(octadecanoylamino)propyl]azanium;ethyl sulfate Chemical compound CCOS([O-])(=O)=O.CCCCCCCCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC WBJQGBBEPJLNKP-UHFFFAOYSA-N 0.000 description 1
- 229960003976 etidocaine Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 150000002193 fatty amides Chemical class 0.000 description 1
- ZWJINEZUASEZBH-UHFFFAOYSA-N fenamic acid Chemical class OC(=O)C1=CC=CC=C1NC1=CC=CC=C1 ZWJINEZUASEZBH-UHFFFAOYSA-N 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- YNDMEEULGSTYJT-LURJTMIESA-N foslevodopa Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C(O)=C1 YNDMEEULGSTYJT-LURJTMIESA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- NMIYNWDARZCKJG-UHFFFAOYSA-N heptatriacontan-19-ylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCCC([NH3+])CCCCCCCCCCCCCCCCCC NMIYNWDARZCKJG-UHFFFAOYSA-N 0.000 description 1
- XYSJYAQKIAGPFT-UHFFFAOYSA-N heptatriacontan-19-ylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCCC([NH3+])CCCCCCCCCCCCCCCCCC XYSJYAQKIAGPFT-UHFFFAOYSA-N 0.000 description 1
- XQSBLCWFZRTIEO-UHFFFAOYSA-N hexadecan-1-amine;hydrobromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[NH3+] XQSBLCWFZRTIEO-UHFFFAOYSA-N 0.000 description 1
- URXQDXAVUYKSCK-UHFFFAOYSA-N hexadecyl(dimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[NH+](C)C URXQDXAVUYKSCK-UHFFFAOYSA-N 0.000 description 1
- ZWGTVKDEOPDFGW-UHFFFAOYSA-N hexadecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[NH3+] ZWGTVKDEOPDFGW-UHFFFAOYSA-N 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- 229960001715 hexamidine isethionate Drugs 0.000 description 1
- TZMQHOJDDMFGQX-UHFFFAOYSA-N hexane-1,1,1-triol Chemical compound CCCCCC(O)(O)O TZMQHOJDDMFGQX-UHFFFAOYSA-N 0.000 description 1
- QVTWBMUAJHVAIJ-UHFFFAOYSA-N hexane-1,4-diol Chemical compound CCC(O)CCCO QVTWBMUAJHVAIJ-UHFFFAOYSA-N 0.000 description 1
- 229960005388 hexylcaine Drugs 0.000 description 1
- 229920002674 hyaluronan Chemical class 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- RNYJXPUAFDFIQJ-UHFFFAOYSA-N hydron;octadecan-1-amine;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[NH3+] RNYJXPUAFDFIQJ-UHFFFAOYSA-N 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- CFUQBFQTFMOZBK-QUCCMNQESA-N ibazocine Chemical compound C12=CC(O)=CC=C2C[C@H]2N(CC=C(C)C)CC[C@]1(C)C2(C)C CFUQBFQTFMOZBK-QUCCMNQESA-N 0.000 description 1
- 229960004187 indoprofen Drugs 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- 229960002064 kanamycin sulfate Drugs 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940100491 laureth-2 Drugs 0.000 description 1
- 229940057905 laureth-3 Drugs 0.000 description 1
- 229940061515 laureth-4 Drugs 0.000 description 1
- LAPRIVJANDLWOK-UHFFFAOYSA-N laureth-5 Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCO LAPRIVJANDLWOK-UHFFFAOYSA-N 0.000 description 1
- 229940031674 laureth-7 Drugs 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960000826 meclocycline Drugs 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 229940042016 methacycline Drugs 0.000 description 1
- 229940051860 methacycline hydrochloride Drugs 0.000 description 1
- HDUDWASHBFYNTJ-UHFFFAOYSA-N methyl N-(6-benzoyl-1H-benzimidazol-2-yl)carbamate hydrochloride Chemical compound Cl.C=1C=C2NC(NC(=O)OC)=NC2=CC=1C(=O)C1=CC=CC=C1 HDUDWASHBFYNTJ-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 229960002421 minocycline hydrochloride Drugs 0.000 description 1
- OJGQFYYLKNCIJD-UHFFFAOYSA-N miroprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C1=CN(C=CC=C2)C2=N1 OJGQFYYLKNCIJD-UHFFFAOYSA-N 0.000 description 1
- 229950006616 miroprofen Drugs 0.000 description 1
- VHDPPDRSCMVFAV-UHFFFAOYSA-N n,n-dimethylhexadecan-1-amine;hydrobromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[NH+](C)C VHDPPDRSCMVFAV-UHFFFAOYSA-N 0.000 description 1
- DULAEBAGAYVIDN-UHFFFAOYSA-N n-dodecyl-n-methyldodecan-1-amine;hydrochloride Chemical compound [Cl-].CCCCCCCCCCCC[NH+](C)CCCCCCCCCCCC DULAEBAGAYVIDN-UHFFFAOYSA-N 0.000 description 1
- UNAFTICPPXVTTN-UHFFFAOYSA-N n-dodecyldodecan-1-amine;hydrobromide Chemical compound [Br-].CCCCCCCCCCCC[NH2+]CCCCCCCCCCCC UNAFTICPPXVTTN-UHFFFAOYSA-N 0.000 description 1
- PEQJBOMPGWYIRO-UHFFFAOYSA-N n-ethyl-3,4-dimethoxyaniline Chemical compound CCNC1=CC=C(OC)C(OC)=C1 PEQJBOMPGWYIRO-UHFFFAOYSA-N 0.000 description 1
- WDCBNBIPWJAFDZ-UHFFFAOYSA-N n-hexadecyl-n-methylhexadecan-1-amine;hydrochloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[NH+](C)CCCCCCCCCCCCCCCC WDCBNBIPWJAFDZ-UHFFFAOYSA-N 0.000 description 1
- FFJMLWSZNCJCSZ-UHFFFAOYSA-N n-methylmethanamine;hydrobromide Chemical compound Br.CNC FFJMLWSZNCJCSZ-UHFFFAOYSA-N 0.000 description 1
- ZLDPNFYTUDQDMJ-UHFFFAOYSA-N n-octadecyloctadecan-1-amine;hydrobromide Chemical compound Br.CCCCCCCCCCCCCCCCCCNCCCCCCCCCCCCCCCCCC ZLDPNFYTUDQDMJ-UHFFFAOYSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229960000808 netilmicin Drugs 0.000 description 1
- 229960004832 netilmicin sulfate Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- YHIXOVNFGQWPFW-UHFFFAOYSA-N octadecan-1-amine;hydrobromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[NH3+] YHIXOVNFGQWPFW-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 229960004368 oxytetracycline hydrochloride Drugs 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 1
- 229960001914 paromomycin Drugs 0.000 description 1
- 229960005065 paromomycin sulfate Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229960000851 pirprofen Drugs 0.000 description 1
- PIDSZXPFGCURGN-UHFFFAOYSA-N pirprofen Chemical compound ClC1=CC(C(C(O)=O)C)=CC=C1N1CC=CC1 PIDSZXPFGCURGN-UHFFFAOYSA-N 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001748 polybutylene Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940078492 ppg-17 Drugs 0.000 description 1
- 229960001896 pramocaine Drugs 0.000 description 1
- DQKXQSGTHWVTAD-UHFFFAOYSA-N pramocaine Chemical compound C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 DQKXQSGTHWVTAD-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 150000005599 propionic acid derivatives Chemical class 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 231100000051 skin sensitiser Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Chemical class 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000005127 stratified epithelium Anatomy 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 229960004477 tobramycin sulfate Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 1
- SZEMGTQCPRNXEG-UHFFFAOYSA-M trimethyl(octadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C SZEMGTQCPRNXEG-UHFFFAOYSA-M 0.000 description 1
- 150000004072 triols Chemical class 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 150000003668 tyrosines Chemical class 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940118846 witch hazel Drugs 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/062—Oil-in-water emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/416—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cosmetics (AREA)
Abstract
本发明涉及轻松皮肤的水包油型护肤组合物,其含有(A)大约0.05%~20%的溶解度参数优选大约在6~12之间的酸性活性成分;(B)大约0.1%~25%的烷氧基醇、烷氧基多元醇和它们的混合物;(C)大约1%~20%的一个酸稳定的,憎水性的结构化试剂,它可以从由饱和的C16到C30的脂肪醇、含有大约1~5摩尔的环氧乙烷的饱和的C16到C30的脂肪醇、饱和的C16到C30的二元醇、饱和的C16到C30的单甘油醚、饱和的C16到C30的羟基脂肪酸和它们的混合物构成的集合中选择,同时要有大约至少45℃的熔点;(D)大约0.05%~10%的一个酸稳定的亲水性的表面活性剂,可以从由阴离子、阳离子、两性离子、非离子型表面活性剂以及它们的混合物构成的集合中选择;(F)大约25%~99.7%的水,其中组合物的pH值大约是3.5或者更低。这些化妆品组合物提供了改进的物理的和化学的稳定性,同时提供了具有很好的活性物质的皮肤沉积作用以及良好的活性物质的皮肤渗透作用,也提供了低水平的皮肤刺激。
Description
技术领域
本发明涉及含有酸性活性物质(例如水杨酸)的水解稳定的低PH值的轻松皮肤的(1eave-on)的护肤化妆品组合物。特别是它涉及了有液体结晶相的稳定的低PH值的化妆品组合物,其提供了改进的润湿作用和水合作用以及改进的物理化学稳定性和低水平的皮肤刺激。
发明背景
目前,人们已经知道了用于处理各种皮肤条件的许多种酸性活性成份。不幸的是,将这些酸性活性物质配制成稳定的水包油型乳液是比较困难的,部分是因为它们的酸性的本质和它们的有限的溶解度特性。这些活性成份的代表物是水杨酸。
在本领域中,含有水杨酸的化妆品组合物是已知的。它们有助于增加皮肤细胞的更新,最后提供看起来更年轻的娇嫩的健康的皮肤。水杨酸是一种很常见的溶角蛋白剂,它被认为可以帮助清除死去的角蛋白以及后面将要描述的皮肤脱落过程。水杨酸也因为它的防粉刺和防皮肤老化等功效而闻名,这一点在C.Huber等人在1977年的Arch.Dem Res.第257期第293~297页上文献中有进一步的描述,在这里该文献作为参考文献。也可以参见于1993年6月10日公开的Blank的PCT专利申请No.9310756。
皮肤由两层构成:表皮(或角质层)和真皮。表皮是一层薄的由层状的上皮构成的外层。表皮的最外层是由薄的类脂层包围的充满蛋白质的角蛋白质扁平细胞组成的角质层。这些细胞通过细胞之间的蛋白(桥粒)互相连接的。在表皮最深处即基层的细胞进行繁殖和生长,将表皮中的老细胞向上推并推向表面。由于这些细胞向上运动,所以它们变得扁平。表皮一般没有血管,并依赖于在真皮中存在的血管来获得营养。表皮层中较外面的细胞,被移动得远离营养供应,逐渐地分化,将它们中的蛋白质变成角蛋白。角蛋白化过程导致了这些细胞的死亡。角蛋白是一种不可溶的蛋白质物质,并赋予角质层一个象角一样的牢固性。最外层的死亡了的角质层细胞逐渐脱落,并被更新的角质化的细胞所代替。
对一个细胞来讲,从表皮的基层移动到角质层的外层并脱去一般大约需要30天。由于细胞从基层向外迁移,它不断地角质化直到它变得比较地不可渗透。结果就是形成了这个角质层,一个极其薄的(10微米)具有坚实的阻挡性质的表层。在角质层内的这些细胞膜常常主要是极性类脂,例如神经酰胺,固醇和脂肪酸,而角质层细胞的细胞质是极性的和含水的。在正常的皮肤内,角质层是以个别细胞或细胞簇的形式脱落的。皮肤问题例如皮肤干燥等就是不正常的皮肤角质化。不正常的皮肤角质化是在皮肤表面的角质层细胞的脱落,没有换成正常的、娇嫩的和健康的皮肤。这样的更换导致了大量细胞簇成为看得到的鳞状皮肤,即在皮肤表面或卵胞中的角质物质或废物和/或一种粗糙的组织在皮肤表面上的一种积累。这些情况可以通过使用含有能够有助于清除最外层角质性的物质的水杨酸的化装品组合物加以改善。
尽管人们已经在使这些酸性活性物质部分中性化方面做了尝试,以改善可调配性并降低对皮肤的刺激性。但是这种方法表明降低了这些酸性活性成份在皮肤中的渗透能力。
因此,需要有效的使酸性活性物质例如水杨酸稳定化的化装品组合物,来从角质层上清除表面鳞片。
因此,提供新的低PH值的含有酸性活性物的水包油乳液就是本发明的一个目标。这些组合物在物理上和化学上是稳定的,同时提供良好的活性物质的皮肤沉积作用和良好的活性物质的皮肤渗透能力,并提供低水平的皮肤刺激。
因此,提供新的组合物通过从角质层上清除干燥皮肤细胞或鳞片以加强皮肤的湿润作用和水合作用是本发明的一个目标。
本发明的一个进一步的目标是提供具有低水平皮肤刺激的组合物,特别是在要求低PH值的组合物中。
本发明的一个进一步的目标是提供具有低水平皮肤刺激的组合物,特别是在要求酸性活性剂的组合物中。
本发明的一个更进一步的目标是提供高级的具有良好的酸性活性成份的稳定性的组合物。
发明概述
本发明涉及轻松皮肤的护肤组合物,其中含有:
(A)大约0.05%~20%的溶解度参数更优选大约在6~12之间的酸性活性成份。
(B)大约0.1%~25%的烷氧基醇、烷氧基多元醇和它们的混合物,它们的分子式为:其中,R可以从由醇、多元醇和它们的混合物组成的集合中选择,要有大约2~10个碳原子的链长;n是大约3~40的一个整数;X可以从由氢、甲基、乙基、丙基或它们的混合物构成的集合中选择。
(C)大约1%~20%的一个酸稳定的,憎水性的起结构作用的试剂,它可以从由饱和的C16到C30的脂肪醇、含有大约1~5摩尔的环氧乙烷的饱和的C16到C30的脂肪醇、饱和的C16到C30的二元醇,饱和的C16到C30的单甘油醚、饱和的C16到C30的羟基脂肪酸和它们的混合物构成的集合中选择,同时要有大约至少45℃的熔点。
(D)大约0.05%~10%的一个酸稳定的亲水性的表面活性剂,可以从由阴离子、阳离子、两性离子、非离子的表面活性剂以及它们的混合物构成的集合中选择。
(F)大约25%~99.7%的水。其中组合物的PH值大约是3.5或者更低,优选的是大约在2.5~3.5之间,更优选大约在2.8~3.2之间。
在另一实施方案中,本发明涉及轻松皮肤的护肤组合物,其中含有:
(A)大约0.1%~5%的水杨酸。
(B)大约0.1%~25%的烷氧基醇、烷氧基多元醇和它们的混合物,它们的分子式为:其中,R可以从由醇、多元醇和它们的混合物组成的集合中选择,要有大约2~10个碳原子的链长;n是大约3~40的一个整数;X可以从由氢、甲基、乙基、丙基或它们的混合物构成的集合中选择。
(C)大约1%~20%的一个酸稳定的,憎水性的起结构作用的试剂,它可以从由饱和的C16到C30的脂肪醇、含有大约1~5摩尔的环氧乙烷的饱和的C16到C30的脂肪醇、饱和的C16到C30的二元醇,饱和的C16到C30的单甘油醚、饱和的C16到C30的羟基脂肪酸和它们的混合物构成的集合中选择,同时要有大约至少45℃的熔点。
(D)大约0.05%~10%的一个酸稳定的亲水性的表面活性剂,可以从由阴离子、阳离子、两性离子、非离子的表面活性剂以及它们的混合物构成的集合中选择。
(F)大约25%~99.7%的水。其中组合物的PH值大约是3.5或者更低,优选的是大约在2.5~3.5之间,更优选大约在2.8~3.2之间。
这里所用的百分比和比例是按在总组合物中所含的重量计算的。所有的测量都是在25℃下进行,除非另有其它说明。本发明包含了这些基本的以及可以选择的在这里被说明的成份或组分,也可以说是由这些成份构成的或基本上是由这些成份构成的。
详细说明
本发明的化装品组合物用于皮肤的润温和水合作用,以及使酸性活性成份向皮肤中沉积。这些组合物是水包油型乳液,其中油相和水相除了包含了这里所说明的基本成份,还包含大量本领域中已知的多种成份。酸性活性成份优选从水包油乳液中的油相中被沉积到皮肤中。因此,这里所用的酸性活性成份的溶解度参数优选大约在6~12之间。
特别是,本发明涉及轻松皮肤的护肤用的水包油型乳液组合物,其中含有:
(A)大约0.05%~20%的溶解度参数优选大约在6~12之间的酸性活性成份。
(B)大约0.1%~25%的烷氧基醇、烷氧基多元醇和它们的混合物,它们的分子式为:其中,R可以从由醇、多元醇和它们的混合物组成的集合中选择,要有大约2~10个碳原子的链长;n是大约3~40的一个整数;X可以从由氢、甲基、乙基、丙基或它们的混合物构成的集合中选择。
(C)大约1%~20%的一个酸稳定的,憎水性的起结构作用的试剂,它可以从由饱和的C16到C30的脂肪醇、含有大约1~5摩尔的环氧乙烷的饱和的C16到C30的脂肪醇、饱和的C16到C30的二元醇,饱和的C16到C30的单甘油醚、饱和的C16到C30的羟基脂肪酸和它们的混合物构成的集合中选择,同时要有大约至少45℃的熔点。
(D)大约0.05%~10%的一个酸稳定的亲水性的表面活性剂,可以从由阴离子、阳离子、两性离子、非离子的表面活性剂以及它们的混合物构成的集合中选择。
(F)大约25%~99.7%的水。其中组合物的PH值大约是3.5或者更低,优选的是在2.5~3.5之间,更优选大约在2.8~3.2之间。
组份(C)和(D)的比例大约应该在20∶1~1∶1之间,优选的是大约在10∶1~1∶1之间,更优选的是大约在5∶1~1∶1之间,大约是3∶1就更好了。这些比例是为了形成一层状的液晶相,从而对在温度大约为-10℃~50℃之间情况下及PH值在3.5左右或者更低时组合物的物理和化学稳定性有利。
本发明的组合物有复杂的流变学特性。这些组合物具有水包油型乳液、液晶以及结晶的凝胶网络的物理特性。
液晶的本质,液晶的形成以及液晶的性质和优点在下面的文献中都有进一步的说明:G.Dahms,“带有各向异性的层状相的水包油乳液的性质”,Cosmetics & Toiletries,第101期,第113-115页,1986年;P.Loll,“在化装品乳液中的液晶”,ICI Surfactants′Publication RP94-93E;G.M.Eccleston,“多相水包油乳液”,J.Soc.Cosmet.Chem.,第41期,第1-22页,1990年1月~2月。在这里,所有这些文献都被作为参考文献。
这里的水包油乳液具有期望的审美学上的和高品质的性质,例如一种柔和的、膏状的而又不油腻的皮肤的感觉。这些乳液可以跨越很大的稠度范围,从稀的洗涤液到重的乳脂。在25℃下用Brookfield Synchro-Lectric D型粘度计测量,一般这些乳液的粘度大约在100cps到500,000cps之间的范围内,优选的是在大约3000~200,000之间,更优选的是大约在5000cps~150,000cps之间,甚至更优选大约在5000cps~100,000cps之间。
这里水包油型乳液组合物是低pH值的。本发明的组合物的pH值是在3.5左右或者更低,优选的是大约在2.5~3.5之间,更优选是在2.8~3.2之间。优选的pH依赖于本发明组合物中所用的特殊的活性剂。例如,对于本发明的酸性活性剂,应该仔细地选择组合物的pH值,以致于它应该等于或低于活性剂的pKa。根据标准定义,一个化合物的pKa是指使其50%离解或电离成其共轭基和一个质子(或水合质子)的pH值。不受理论的限制,当这个组合物的pH值在活性剂的pKa以下时,认为该活性剂主要以其非离解的形式存在,这将增强它向皮肤的沉积。
例如,在19℃的水溶液中,据报道的水杨酸的pKa值是2.97。因此,形成含有水杨酸的pH值为2.97或更低的组合物对于减少其电离以及使其最大程度地向皮肤沉积将是很有用的。参见CRC Handbook of Chemistry andPHysics第57版第D-150页(1976)。
尽管可以用缓冲剂来维持乳液的组合物的pH值,但是它们不是必须的成份,而仅仅是可选的成份。
(A)活性剂成份
本发明的组合物含有安全和有效量的酸性活性剂成份及其混合物,而且这些酸性活性剂优选是溶于本发明组合物的油相中并沉积于皮肤表面上。
这里所用的“安全和有效量”一词,是指以在完善的药品评判的范围内的一个合理的活性组分的用量,该活性剂成份的量要足够高,以致于可以改善要处理的条件,或者可以给皮肤带来所期望的好处,但是又要使其足够低,以致于可以避免严重的副作用。安全和有效量的活性剂成份的含义又将随着不同的活性剂、活性剂渗过皮肤的能力、使用者的年龄、健康状况以及皮肤条件和类似的其它因素而变化。
本发明有代表性的活性剂重量百分比含量是大约在组合物重量的0.05%-20%之间,优选的是大约在0.1%~10%之间,更优选大约在1%-5%之间。这里有用的活性剂的溶解度参数要大约在6-12之间,优选的是大约在7~12之间,更优选大约在9~12之间。对于在本领域中的具有一般技术水平的配制人员来讲,溶解度参数是已知的。溶解度参数一般作为在配制过程中判断各种物料之间的相容度和其溶解度的一个标准。根据实际情况,认为在选择具有上述指定的范围的溶解度参数的活性剂时,活性剂应是憎水性的,即亲油的,因此更易溶于这里的水包油型乳液的油相中。活性剂成份的亲油的本质有助于在用水清洗乳液后,增强活性剂从水包油型乳液向皮肤的沉积。一般来讲,在25℃的水中,具有上述规定范围的溶解度参数的活性剂的溶解度优选约小于l克活性剂/100克水。
1985年CRC出版社出版的Barton,A.F.M.的Handbook of SolubilityParameters一书中的第64-66的第六章的表3收集了大量的原子和原子基团的有关蒸发热和摩尔体积的加成基团贡献标准表,在这里,该文献被全部用来作为参考。上述溶解度参数方程在Fedors,R.F.的“一种估计溶解度参数和液体摩尔体积的方法”一文(Polymer Engineering and Science,第14卷,第2期,第147-154页,1974年2月)中有所说明,这一文献也全部作为参考。
计算的溶解度参数遵守混合规则,即混合物的计算溶解度参数是通过混合物中的各成份的计算溶解度参数加权平均得到的。参见,1976-1977年CRC出版社出版的Handbook of Chemistry and Physics,第57版,第C-726页,这一文献全部作为参考。
配制技术人员一般用(卡/厘米3)作为溶解度参数的单位。在Handbookof Solubility Parameters一书的表中,加成基团的蒸发热的单位是千焦/摩尔。但这些蒸发热的表值可以通过下面已知的关系式转换成卡/摩尔:
1焦/摩尔=0.239006卡/摩尔,1000焦=1千焦参见,1972年John Wiley & Sons出版的Gordon,A.J.等人的文献TheChemist′s Companion的第456-463页,这一文献全部作为参考。
对于大量的化合物都已经有表列出了它们的溶解度参数。在前面提到的Handbook of Solubility Parameters一书中列出了溶解度参数表。
可以根据治疗作用和假设的作用模式给这里所用的活性剂分类。然而,应该明白的是这里所用的活性剂有时可以提供不止一种治疗作用或者是可以执行多种作用形式。因此,为方便起见,这里进行了分类,但不是为了将活性剂限制在列出的特定的一种应用或一些应用中。在Deckner等人的1993年12月2日编入的P&G共同待审专利申请流水号No.08/161,104中的第10-14页,描述了根据治疗作用或作用形式所划分的这里所用的活性剂的类别,这些在这里引入为参考。另外,在本发明组合物中,下面的优选具有上述的溶解度参数的酸性活性剂是有用的。抗粉刺活性剂:有用的抗粉刺活性剂的几个例子包括溶角蛋白剂,例如水杨酸(邻羟基苯甲酸)、水杨酸的衍生物例如5-辛酰水杨酸和间苯二酚;视黄酸类物质例如视黄酸和它的衍生物(例如顺式和反式视黄酸);抗菌素和灭菌剂例如过氧化苯甲酰、羟甲辛吡酮、四环素、2,4,4′-三氯-2′-羟基-二苯醚、3,4,4′-三氯酰苯胺(banilide)、壬二酸及其衍生物、苯氧基乙醇、苯氧基丙醇、苯氧基异丙醇、乙酸乙酯,氯林肯霉素和甲氯环素;sebostats例如类黄酮;胆汁盐例如鲨胆淄醇硫酸盐及其衍生物、脱氧胆酸盐和胆酸盐。
抗皱和抗皮肤萎缩活性剂:抗皱和抗皮肤萎缩活性剂的几个例子包括视黄酸、水杨酸和去皮剂(例如苯酚)。非甾族抗炎活性剂(NSAIDS):NSAIDS的例子包括下列类型:丙酸衍生物、乙酸衍生物、灭酸衍生物、联苯基羧酸衍生物和oXicams。所有这些NSAIDS都在1991年1月15日发表的Sunshine等人的美国专利4,985,459中有充分的说明,在这里作为参考。有用的NSAIDS的几个例子包括己酰水杨酸、异丁苯丙酸、甲氧萘丙酸、苯恶丙芬、氟联丙酸、苯氧苯丙酸、联苯丁酮酸、酮苯丙酸、茚酮苯丙酸、吡丙芬、卡洛芬、恶哌拉嗪、双吡苯丙酸、咪洛芬、苯恶硫丙酸、噻丙吩、苯铝酸、苯噻丙酸、氟苯丙酸和布氯酸。包括氢化可的松的甾族的抗炎药物也是有用的。局部麻醉剂:几个局部麻醉剂的例子包括苯坐卡因、利度卡因盐酸盐、丁哌卡因、氯丙卡因、狄布卡因、衣铁卡因、卡波卡因、丁卡因、达克罗宁、己卡因、普鲁卡因、可卡因、氯胺酮、丙吗卡因、苯酚和它们的药物上可以接受的盐。促鞣剂:人工的用于鞣制的成份和促鞣剂包括二羟基酮。抗菌和抗真菌活性剂:抗菌和抗真菌活性剂的例子有:b-内酰胺类药、喹诺酮类药物、环丙氟氯霉素、诺氟沙星、四环素、红霉素、阿米卡星、2,4,4′-三氯-2′-羟基二苯醚、3,4,4′-三氯banilide、苯氧基乙醇、苯氧基丙醇、苯氧基异丙醇、强力霉素、缠霉素、洗必汰、金霉素、土霉素、氯林肯霉素、乙氨丁醇、羟乙磺酸己脒定、甲哨唑、戊脒定、庆大霉素、卡那霉素、线霉素,甲烯土霉素、乌洛品托、二甲胺四环素、新霉素、奈替米星、巴龙霉素、链霉素、托普霉素、双氯苯咪唑、四环素、盐酸化物、红霉素、锌红霉素、无味红霉素、红霉素硬脂酸盐、硫酸阿米卡星、多西环素盐酸盐、硫酸卷曲霉素、葡萄糖酸洗必汰、盐酸洗必汰、盐酸金霉素、盐酸土霉素、盐酸氯林肯霉素、盐酸乙氨丁醇、盐酸甲哨唑、盐酸戊脒定、硫酸庆大霉素、硫酸卡那霉素、盐酸线霉素、盐酸甲烯土霉素、马尿酸乌洛托品、扁桃酸乌洛托品、盐酸二甲胺四环素、硫酸新霉素、硫酸奈替米星、硫酸巴龙霉素、硫酸链霉素、硫酸托普霉素、盐酸双氯苯咪唑、盐酸amanfadine、硫酸amanfadine、羟甲辛吡酮、对氯间二甲苯酚、制霉菌素、癣退和克霉唑。防晒活性剂:在这里某些防晒剂是有用的。各种各样的防晒剂在下列文献中都有说明:1992年2月11日授权的Haffey等人的美国专利No.5,087,445;1991年12月17日授权的Turner等人的美国专利No.5,073,372;1991年12月17日授权的Turner等人的美国专利No.5,073,371;Segarin等人的Cosmetics Science and Technology一书中第八章第189页。所有上述文献全文在这里都全文作为参考。几个非限制性的的防晒活性剂的例子可以从由对氨基苯甲酸、2-苯基苯并咪唑-5-磺酸以及它们的混合物构成的集合中选择。其它的有用的防晒剂在1990年6月26日授权的Sabatelli等人的美国专利No.4,937,370和1991年3月12日授权的Sabatelli等人的美国专利No.4,999,186上都有说明。这两篇文献在这里都全文作为参考。
这里“水杨酸”一词包括水杨酸及其衍生物,例如5-辛基水杨酸。
这里有用的几个优选的活性剂的例子包括水杨酸、3-羟基苯甲酸、4-羟基苯甲酸、乙酰基水杨酸、2-羟基丁酸、2-羟基戊酸、2-羟基己酸、顺-视黄酸、反-视黄酸、壬二酸、花生四烯酸、过氧化苯甲酸、四环素、异丁苯丙酸、甲氧萘丙酸、氢化可的松、acetominophen、间苯二酚、苯氧基乙醇、苯氧基丙醇、苯氧基异丙醇、2,4,4′-三氯-2′-羟基二苯醚、3,4,4′-三氯对称二苯脲、羟甲辛吡酮、利度卡因盐酸盐、克霉唑、双氯苯咪唑、硫酸neocycin、对氨基苯甲酸、2-苯基苯并咪唑-5-磺酸、二羟基丙酮和它们的混合物。
在这里有用的更好的几个活性剂的例子包括水杨酸、乙酰基水杨酸、顺-视黄酸、反-视黄酸、壬二酸、四环素、异丁苯丙酸、甲氧萘丙酸、acetominophen、氢化可的松、间苯二酚、苯氧基乙醇、苯氧基丙醇、苯氧基异丙醇、2,4,4′-三氯-2′-羟基二苯醚、3,4,4′-三氯对称二苯脲、羟甲辛吡酮、2-苯基苯并咪唑-5-磺酸、二羟基丙酮和它们的混合物。
在这里有用的最优选的几个活性剂的例子包括水杨酸、顺-视黄酸、反-视黄酸、壬二酸、间苯二酚、异丁苯丙酸、甲氧萘丙酸、氢化可的松、苯氧基乙醇、苯氧基丙醇、苯氧基异丙醇、2,4,4′-三氯-2′-羟基二苯醚、3,4,4′-三氯对称二苯脲、2-苯基苯并咪唑-5-磺酸、二羟基丙酮和它们的混合物。
在这里有用的一个特别要优选的活性剂是在大约组合物的0.1%~5%重量含量的水杨酸,优选的是在组合物的大约1%~3%重量含量,更优选的是在组合物的大约1%~3%重量含量。
上述列出的活性剂也包括这些酸性活性剂的盐,只要这些盐能在本发明的组合物中能保持酸性。
(B)烷氧基化醇
本发明的组合物包含大约0.1%~15%,优选约0.1%至约15%,更好的是大约6%~10%的烷氧基醇和/或烷氧基多元醇,它们起稳定在水包油乳液的油相中的酸性活性剂的作用。用于这里的这些烷氧基醇和或烷氧基多元醇是憎水性的,在25℃的水中的溶解度小于1克/100克水左右。优选是这些溶剂中要至少含有10-20摩尔的氧化丙烯。这些化合物一般要配制入水包油乳液的油相中,下面将要对此进行说明。这里可以使用烷氧基醇和或烷氧基多元醇的混合物。用于这里的烷氧基醇可以用下列通式说明:其中,R可以从由醇、多元醇、二元醇和它们的混合物组成的集合中选择,要有大约2~10个碳原子的链长;n是大约3~40的一个整数;X可以从由氢、甲基、乙基、丙基或它们的混合物构成的集合中选择。
优选的是,从由醇、多元醇、二元醇和它们的混合物组成的集合中选择选择R,并要有大约4~16个碳原子的链长;X是甲基;n是大约6~35的一个整数。优选的是,从由醇、多元醇、二元醇和它们的混合物组成的集合中选择选择R,并要有大约4~6个碳原子的链长;X是甲基;n是大约10~20的一个整数。
这里有用的几个非限制性的烷氧基醇的例子包括醇和多元醇的丙氧基和丁氧基醚。这些化合物可以用PPG和PBG烷基醚来表示,其中PPG和PBG一般分别代表聚丙二醇和聚丁二醇。PPG和PBG基团在这些醚中的平均数通常由在PPG和PBG后面的一个数来代表。例如,PPG-14丁醚表示丁醇的聚丙二醇醚,其中其分子平均有14个聚丙二醇单元。
这里有用的几个非限制性的烷氧基醇的例子包括PPG-10丁醚、PPG-11丁醚、PPG-12丁醚、PPG-13丁醚、PPG-14丁醚、PPG-15丁醚、PPG-16丁醚、PPG-17丁醚、PPG-18丁醚、PPG-19丁醚、PPG-20丁醚、PPG-22丁醚、PPG-24丁醚、PPG-30丁醚、PPG-11硬脂醚、PPG-15硬脂醚、PPG-10油醚、PPG-7月桂醚、PPG-30异十六烷基醚、PPG-10甘油醚、PPG-15甘油醚、PPG-10丁二醇醚、PPG-15丁二醇醚、PPG-27甘油醚、PPG-30十六烷基醚、PPG-28十六烷基醚、PPG-10十六烷基醚、PPG-10己二醇醚、PPG-15己二醇醚、PPG-10 1,2,6-己三醇醚、PPG-15 1,2,6-己三醇醚以及它们的混合物。
优选的烷氧基醇要从由PPG-14丁醚、PPG-15硬脂醚、及其混合物构成的集合选择。
更优选的烷氧基醇要从由PPG-14丁醚、PPG-15硬酯醚、及其混合物构成的集团中选取。它们以Union Carbide公司的Fluid AP为商品名的PPG-14丁醚是可以买到的。以ICI Americas公司的Arlamol E为商品名的PPG-15硬脂醚是可以买得到的。
这里有用的几个非限制性的烷氧基多元醇的例子可以从由PPG-10 1,4-丁二醇、PPG-12 1,4-丁二醇、PPG-14 1,4-丁二醇、PPG-2丁二醇、PPG-101,6-己二醇、PPG-12 1,6-己二醇、PPG-14己二醇、PPG-20己二醇及其混合物构成的集合中选择。优选的是从由PPG-10 1,4-丁二醇、PPG-12 1,4-丁二醇、PPG-10 1,6-己二醇、PPG-12己二醇及其混合物构成的集合中选择。更优选的是PPG-10 1,4-丁二醇。以PPG/Mazer公司的Macol 57为商品名的这种化合物是可以买到的。
(C)酸稳定的憎水的结构化试剂
本发明也含有一种浓度大约在1%~20%之间,优选的是大约在1%~10%之间,更优选的是大约在3%~9%之间的酸稳定的憎水的结构化试剂,它可以从由饱和的C16-C30脂肪醇、含有大约1-5摩尔环氧乙烷的饱和的C16-C30脂肪醇、饱和的C16-C30二元醇、饱和的C16-C30单甘油醚、饱和的C16-C30羟基脂肪酸以及它们的混合物构成的集合中选择,同时它的熔点至少为45℃。这些结构化试剂在帮助形成本组合物的流变学特征方面是很有用处的,这有助于增强本发明组合物的水解稳定性。
本发明的结构化试剂要从由十八烷醇、十六烷醇、平均大约有1-5个环氧乙烷单元的十八烷醇的聚乙二醇醚、平均大约有1-5个环氧乙烷单元的十六烷醇的聚乙二醇以及它们的混合物构成的集合中选择。优选的结构化试剂要从由十八烷醇、十六烷醇、平均大约有2个环氧乙烷单元的十八烷醇的聚乙二醇(steareth-2)、平均大约有2个环氧乙烷单元的十六烷醇的聚乙二醇以及它们的混合物构成的集合中选择。更优选的结构化试剂是从由十八烷醇、十六烷醇、steareth-2以及它们的混合物构成的集合中选择。更优选的选择是steareth-2,以ICI Americas公司的Brij72为商品名的steareth-2是可以得到的。
(D)酸稳定的亲水的表面活性剂
本发明组合物含有至少一种含量大约在0.05%~10%之间,优选的是大约在1%~6%之间,更优选大约在1%~3%之间的酸稳定的亲水的表面活性剂,它可以分散在水相中的憎水性物质。该表面活性剂至少要亲水以能够在水中足够地分散。这里表面活性剂用于乳化油水相成份和稳定得到的乳液。
这里有用的表面活性剂包括大量的非离子的、阳离子的、阴离子和两性离子的表面活性剂,这些在以前的专利和其它参考文献中都有说明。参见,1986年由Allured Publishing Corporation出版的McCutcheon的Detergents and Emulsifiers(北美版);1991年4月30日授权的Ciotti等人的美国专利No.5,011,681;1983年12月20日授权的Dixon等人的美国专利No.4,421,769;1973年8月28日授权的Dickert等人的美国专利No.3,755,560;这四篇文献在这里全文作为参考。
选择确切的乳化剂要根据组合物的PH值和存在的其它成份。合适的表面活性剂类型包括四烷基铵盐、乙氧基醇、脂肪酰胺以及它们的混合物。这里优选阳离子乳化剂,特别是二烷基季铵盐化合物。这里有用的各种阳离子表面活性剂在下列文献中都有说明:1992年9月29日授权的McCall等人的美国专利No.5,151,209;1992年9月29日授权的Steuri等人的美国专利No.5,151,210;1992年6月9日授权的Wells等人的美国专利No.5,120,532;1983年6月7日授权的Bolich的美国专利No.4,387,090;1964年11月3日授权的Hilfer的美国专利No.3,155,591;1975年12月30日授权的Laughlin等人的美国专利No.3,929,678;1976年5月25日授权的Bailey等人的美国专利No.3,959,461;1979年M.C.Publishing Co.出版公司的McCutcheon′s Detergents & Emulsifiers(北美版);1949年IntersciencePublishers于纽约出版的Schwartz等人的Surface Active Agents,TheirChemistry and Technology。所有这些文献在这里都全文作为参考。这里有用的阳离子表面活性剂包括有下列分子式的阳离子铵盐:其中,R1是一个含有大约12~30个碳原子的烷基,或者含有大约12~30个碳原子的芳香族的芳基或烷芳基;R2、R3和R4要各自从氢、含有大约1~22个碳原子的烷基或者含有大约12~22个碳原子的芳香族的芳基或烷芳基中选择;X是任何相匹配的阴离子,更优选从由氯、溴、碘、乙酸根、磷酸根、硝酸根、硫酸根、甲基硫酸盐、乙基硫酸盐、甲苯磺酸根、乳酸根、柠檬酸根、甘醇酸酯以及它们的混合物构成的集合中选择。另外,烷基R1、R2、R3和R4也可以含有酯键和/或醚键,或者羟基或氨基取代基(例如,烷基可以含有聚乙二醇和聚丙二醇部分)。
更优选的是,R1是一个含有大约12~22个碳原子的烷基;R2从H或含有大约1~22个碳原子的烷基中选择;R3和R4从氢、含有大约1~3个碳原子烷基中选取;X则如前所述。
最优选的是,R1是一个含有大约12~22个碳原子的烷基;R2、R3和R4从氢、含有大约1~3个碳原子烷基中选择;X则如前所述。
作为一个替代的办法,其它有用的阳离子乳化剂包括氨基酰胺,其中上述的结构中R1替换为R5CO-(CH2)n-,其中R5是含有大约12~22个碳原子的烷基,n是大约2~6的一个整数,优选的是大约2~4的一个整数,更优选的是大约2~3的一个整数。非限制性的这些阳离子乳化剂包括硬脂酰胺基丙基氯化磷酸PG-二希土元素,硬脂酰胺基丙基乙硫酸(ethosulfate)乙基二希土元素,硬脂酰胺基丙基二甲基(十四烷基己酸)氯化铵,硬脂酰胺基丙基二甲基ceteary甲苯磺酸铵,硬脂酰胺基丙基二甲基氯化铵、硬脂酰胺基丙基二甲基乳酸铵以及它们的混合物。
非限制性的季铵盐阳离子乳化剂几个例子可以是从由十六烷基氯化铵、十六烷基溴化铵、十二烷基氯化铵、十二烷基溴化铵、硬脂基氯化铵、硬脂基溴化铵、十六烷基二甲基氯化铵、十六烷基二甲基溴化铵、十二烷基二甲基氯化铵、十二烷基二甲基溴化铵、硬脂基二甲基氯化铵、硬脂基二甲基溴化铵、十六烷基三甲基氯化铵、十六烷基三甲基溴化铵、十二烷基三甲基氯化铵、十二烷基三甲基溴化铵、硬脂基三甲基氯化铵、硬脂基三甲基溴化铵、十二烷基二甲基氯化铵、硬脂基二甲基十六烷基二动物脂二甲基氯化铵、二-十六烷基氯化铵、二-十六烷基溴化铵、二-十二烷基氯化铵、二-十二烷基溴化铵、二-硬脂基氯化铵、二-硬脂基溴化铵、二-十六烷基甲基氯化铵、二-十六烷基甲基溴化铵、二-十二烷基甲基氯化铵、二-十二烷基甲基溴化铵、二-硬脂基甲基氯化铵、二-硬脂基甲基溴化铵以及它们的混合物构成的集合中选择的那些例子。其它的的季铵盐包括那些其中C12-C30烷基碳链是由动物脂脂肪酸或椰子脂肪酸衍生的。其中“动物脂”一词是指一个由通常含C16~C18范围内的烷基的混合物的动物脂肪酸衍生的烷基(通常是加氢的动物脂肪酸),而“椰子”一词是指由通常含C12~C14的烷基混合物的椰子脂肪酸衍生的一个烷基。由这些动物脂和椰子得到的几个季铵盐的例子包括二动物脂二甲基氯化铵,二动物脂二甲基甲基硫酸铵、二(加氢动物脂)二甲基氯化铵、二(加氢动物脂)二甲基醋酸铵、二动物脂二甲基磷酸铵、二动物脂二甲基硝酸铵、二(椰子烷基)二甲基氯化铵、二(椰子烷基)二甲基溴化铵、动物脂氯化铵、椰子基氯化铵、硬脂酰胺基丙基酸PG-二希土元素、硬脂酰胺基丙基乙硫酸乙基二希土元素、硬脂酰胺基丙基二甲基(十四烷基乙酸)氯化铵,硬脂酰胺基丙基二甲基cetearyl甲苯磺酸铵、硬脂酰胺基丙基二甲基氯化铵、硬脂酰胺基丙基二甲基乳酸铵以及它们的混合物构成的集合中选择。
更优选的阳离子表面活性剂可以从由二-十二烷基二甲基氯化铵、二-硬脂基二甲基氯化铵、二-十四烷基二甲基氯化铵、二-十六烷基二甲基氯化铵、二-硬脂基二甲基氯化铵、硬脂酰胺基丙基氯化磷酸PG-二希土元素、硬脂酰胺基丙基乙硫酸乙基二希土元素、硬脂酰胺基丙基二甲基(十四烷基乙酸)氯化铵,硬脂酰胺基丙基二甲基cetearyl甲苯磺酸铵、硬脂酰胺基丙基二甲基氯化铵、硬脂酰胺基丙基二甲基乳酸铵以及它们的混合物构成的集合中选择。
最优选的阳离子表面活性剂可以从由二-十二烷基二甲基氯化铵、二-硬脂基二甲基氯化铵、二-十四烷基二甲基氯化铵、二-十六烷基二甲基氯化铵及其混合物构成的集合中选择。
某些非离子表面活性剂也是可以选用的,特别是当与上述阳离子乳化剂共同使用时。已经发现,一种高HLB的非离子表面活性剂和一种低HLB的非离子表面活性剂的混合物是特别优选的。根据实际情况,这种高HLB的非离子表面活性剂和低HLB的非离子表面活性剂的混合物可以使组合物表现出增强的乳化稳定性能。缩写“HLB”代表亲水亲油平衡。HLB系统在本领域中是已知的,在1984年8月ICI Americas Inc.公司出版的“TheHLB System,A Time-Saving Guide to Emulsifier Selection”一书中有其详细的说明,这里引用作为参考。
根据这里的定义,高HLB非离子表面活性剂包括任何已知的HLB值大约为至少6~18,优选的是大约从8~18、更优选大约从10~18的非离子表面活性剂。这些高HLB的非离子表面活性剂不包括HLB值小于6的那些乳化剂,这一点在下面将要进行说明。这些典型的高HLB非离子乳化剂是乙氧基或丙氧基,优选乙氧基醇和烷基苯酚(尤其优选醇的衍生物)。这些醇的衍生物含有在C8-30,优选的是C10-22,更优选的是C12-20范围内的直链或支链烷基,一般含有大约从6-30,更优选是从6-25个氧化乙烯或氧化丙烯基团。在这些乙氧基和丙氧基醇中,最优选乙氧基衍生物。这里优选的选择是选用由十二醇、十六烷醇、油醇、十八烷醇、异十八烷醇、十四醇、二十二醇以及它们的混合物衍生的聚环氧乙烷醚。这里更优选的是已知的聚氧乙烯10十六烷醚(在CTFA中是用ceteth-10来代表的)、聚氧乙烯(21)硬脂醚(在CTFA中是用steareth-21来代表的)、椰子烷基聚氧乙烯(6.5)、癸基聚氧乙烯(6)以及它们的混合物。这里最优选是选用ceteth-10、steareth-21以及它们的混合物。
在1984年由MC Publishing Corporation,McCutcheon Division出版的McCutcheon的Detergents and Emulsifiers(北美版)一书中详细的列出了HLB非离子乳化剂,这本书已经被作为这里的参考文献。
这里低HLB非离子表面活性剂是指任何具有大约从1到小于6的已知的HLB值的非离子表面活性剂。这些低HLB非离子表面活性剂不包括上述说明的高HLB非离子表面活性剂。
这些低HLB非离子乳化剂的例子是乙氧基醇,其中这些醇的衍生物含有在C8-30,优选的是C10-22,更优选的是C12-20范围内的直链或支链烷基,并且一般每分子含有大约1-5个环氧乙烷基。
这里有用的几个非限制性的低HLB非离子乳化剂的例子包括带有1摩尔环氧乙烷的乙氧基十二醇(即laureth-1)、laureth-2、laureth-3、laureth-4、laureth-5以及它们的混合物。
有关低HLB乳化剂的详细情况在1984年由MC出版公司McCutcheonDivision出版的McCutcheon的EMULSIFIERS AND DETERGENTS(北美版)一书中可以找到,这本书已经在这里被作为参考文献。
在本发明中,我们发现当低HLB非离子乳化剂和高HLB非离子乳化剂混在一起使用时,更优选要选用steareth-21和/或带有steareth-2的ceteth-10的混合物。
(E)水
本发明的组合物含有大约25%~99.7%、优选的是大约65%~95%、更优选的是大约70%~90%的水。
可以选择的成份
在乳液的水相和油相中都包含大量的可选择的成份。这种典型的可选择的成份是:聚丙二醇:这里使用的含量是组合物重量的大约1%-5%之间,更优选是在2%-3.5%之间,以增强本发明组合物的酸性活性剂成份的渗透能力。聚丙二醇一般是由氧化丙烯、丙二醇、丙基氯乙醇、丙基溴乙醇以及其它有关物质聚合形成的。用下列分子式表示聚丙二醇:其中,n是一个大约10-50,优选的是大约15-40,更优选大约20-34的一个整数。在上述结构中,尽管为了方便描述了一个同分异构取向,但是这个描述并不排除其它的同分异构结构。聚丙二醇通常是用带有表示在该结构中的平均单元个数的一个整数的PPG来表示。例如,PPG-30对应上述结构,其中n是约30的平均值。根据这一命名法,这里有用的聚丙二醇包括用PPG-10~PPG-50表示的,更好的是用PPG-15~PPG-40表示的,更优选用PPG-20~PPG-34表示的聚丙二醇。湿润剂:本发明的组合物中的另一个优选成份是湿润剂。用于这里时,湿润剂要占本组合物重量的大约0.1%~20%,优选的大约是0.5%~10%,更优选的大约是1%~5%。尽管在这里这些物质被定义为湿润剂,但是它们也可以拥有润湿、调节皮肤以及其它有关的性质。
这里有用的湿润剂包括脲、胍、饱和或不饱和的烷基α一羟基酸例如甘醇酸和甘醇酸盐(例如铵和季化烷基铵),乳酸和乳酸盐(例如铵和季化烷基铵),还有不同形式的芦荟(例如芦荟凝胶);聚羟基醇例如山梨醇、甘油、低分子量聚丙二醇(例如二亚丙基二醇,三亚丙基二醇)、己三醇、丙二醇、丁二醇、己二醇等;聚乙二醇;糖和淀粉;糖和淀粉的衍生物(例如烷氧基葡萄糖)、透明质酸;聚乙酰氨基葡糖、淀粉接枝的聚丙烯酸钠例如Sanwet(RTM)IM-1000,IM-1500和IM-2500(在Portsmouth,VA的Celanese Superabsorbent Materials可以得到);乳酰胺单乙醇胺;乙酰胺单乙醇胺;丙氧基化甘油(在1990年12月11日授权Orr等人的美国专利No.4,976,953中有所说明,这篇文献在这里已经作为参考文献)以及它们的混合物。
在本发明的组合物中更优选的湿润剂是脲、C3-C6二元醇和三元醇、低分子量聚丙二醇、丙氧基甘油。优选的湿润剂可以从由脲、丙二醇、1,3-二羟丙烷、甘油、丁二醇、己二醇、1,4-二羟基己烷、1,2,6-己三醇、二亚丙基二醇、三亚丙基二醇以及它们的混合物构成的集合中选择。更优选的湿润剂可以从由脲、甘油、丙二醇、己二醇、甘油、二亚丙基二醇、三亚丙基二醇以及它们的混合物构成的集合中选择。最优选的湿润剂是丙二醇、脲、甘油以及它们的混合物。润肤剂:本发明的组合物也包括一种润肤剂。合适的润肤剂包括但不限于挥发和不挥发的硅油(例如二甲基聚硅氧烷(dimethicone)、环甲基聚硅氧烷、二甲基聚硅氧醇(dimethiconol)以及类似的物质),高度支化的碳氢化合物以及它们的混合物。在本发明中有用的润肤剂在1990年4月24日授权Deckner等人的美国专利No.4,919,934中有进一步的说明。
这里典型的湿肤剂的总含量要占本组合物重量的大约0.1%~25%,更好的是0.5%~10%,更优选的是大约0.5%~5%。附加成份:
大量的附加成份可以被用于本发明的组合物中。这些附加成份至少要是酸稳定的。非限制性的附加成份包括维他命及其衍生物(例如维生素E,泛酰醇及其类似物);其它增稠剂(例如聚丙烯酰胺和C13-14异链烷烃和laureth-7,可以从新泽西州Fairfield的Seppic Corp.公司获得的Sepigel305;支化的多糖例如硬葡聚糖,从新泽西州的Mountainside的MichelProducts Inc.公司生产的ClearogelCS 11的商品名可以得到);饱和/或不饱和的烷基α-羟基酸;树脂;树胶(例如瓜尔树胶、黄原胶以及类似物);蜡(自然的和合成的);有助于组合物的成膜和牢固性的聚合物(例如二十烯和乙烯基吡咯烷酮的共聚物,其中的一个例子是GAFChemical Corporation公司的商品名为Ganex V-200的物质);用于清洗和剥离除皮肤污物的磨砂颗粒[例如位于新泽西州的Morristown的AlliedSignal Inc.公司的产品ACuscrub柔和磨洗剂(例如ACuscrub30,31,32,40,41,42,43,44,50,51和52);位于MN州的St.Paul的3M公司的产品3M Brand PMU Capsules微囊化矿物油];用于维护本组合物的抗菌性的防腐剂、皮肤渗透助剂例如DMSO、十二烷基氮杂环庚基-2-酮(Upiohn公司的Azone)及其类似的物质;人造鞣剂成份和促鞣剂,例如酪氨酸、酪氨酸酯例如乙基酪氨酸和二氧磷基-DOPA);皮肤漂白剂(或增白剂)包括但不限于氢醌、曲酸和偏亚硫酸氢盐;螯合剂和多价螯合剂;美学成份例如香料、颜料、染料、香精油、皮肤敏化剂(sensates)、收敛剂、滑肤剂、皮肤恢复剂等等,非限制性的这类美学成份包括泛酰醇和其衍生物(例如乙基泛酰醇)、芦荟、泛酸和其衍生物、丁子香油、薄菏醇、樟脑、按树油、丁子香酚、基乳酸、金缕梅馏出液、尿囊素、红没药醇、甘草酸二钾等等。
优选的是在本组合物中的重量百分比大约在0.05%~5%之间的饱和或不饱和的烷基α-羟基酸,例如乳酸、乳酸盐(例如铵和季化烷基铵)、乙醇酸、乙醇酸盐(例如铵和季化烷基铵)、水果酸。在1993年9月的Soap/Cosmetics/Chemical Specialties第54-59页上Walter P.Smith的文章Hydroxy Acids and Skin Aging一文中有关于α-羟基酸的讨论,这里全部作为参考。
脱皮屑方法
本发明也涉及了一些方法,其中在皮肤上涂上有效剂量的酸性活性成份,以改善要处理的皮肤条件或得到期望的利益。有效剂量是指在完善的药品评判的范围内的以一个合理的用量,用足够的量得到所期望的好处,但是又要使其足够低,以致于可以避免严重的副作用。安全而又有效的使用量的酸性活性剂成份的含义又将随着不同的活性剂、活性剂渗过皮肤的能力、使用者的年龄、使用者的健康状况以及使用者的皮肤条件和类似的其它因素而变化。这样的典型的方法包括向皮肤或头皮施用一个有效量的本发明的组合物。例如,一个有效的含有水杨酸的组合物量是指足可以提供一个相当规模的去除皮屑的使用量,一般大约是0.004~0.1mg/cm2,优选的是大约0.02~0.06mg/cm2,更优选的是0.04mg/cm2左右。这个组合物可以以一定的时间间隔连续使用几天、几个星期、几个月或几年,合适的间隔是大约一天三次到三天一次,优选的是大约一天两次到两天一次,更优选是大约一天一次,直到得到满意的脱皮屑、润温和水合作用。
例子
下面的例子在本发明的范围内进一步地描述和展现本发明的具体情况。给出例子的目的仅仅是为了说明,而不是作为对本发明的限制,因为其中有很多变化都是可能的,而又不背离本发明的实质和范畴。成份都统一用化学名或CTFA名。
例I-II
含水杨酸的轻松皮肤的湿润用产品通过用下述传统的混合技术混合下列成份,来准备一个含有水杨酸的有润湿作用的轻松皮肤的水包油乳液。成份 I II
重量百分比 重量百分比水杨酸 2 1.5PPG-14丁醚 8.00 8.00甘油 4.00 4.00十八烷醇 1.5 1.5十六烷醇 3.00 3.00二硬脂基二甲基氯化铵 0.1 0.1丙二醇 3.00 3.00Steareth-211 2.0 2.0Steareth-22 1.0 1.0二甲基聚硅氧烷3 1.0 1.0环甲基聚硅氧烷4 1.0 1.0EDTA二钠 0.02 0.02次要成份 0.07 0.07水 QS100 QS1001是大约平均含有21摩尔的环氧乙烷的十八烷醇的聚乙二醇。2是大约平均含有2摩尔的环氧乙烷的十八烷醇的聚乙二醇。3是用三甲基二氧基团封端的完全甲基化的线性硅氧烷聚合物的混合物。4是环二甲基聚硅氧烷的化合物
按下面步骤准备上述组合物:
首先准备水相。即将水加热到大约180°F(82℃),然后加入二硬脂基二甲基氯化铵、甘油和丙二醇。保持此混合物在大约65℃~75℃。
在一个单独的容器中,准备油相。即将十六烷醇、十八烷醇、Steareth-2、Steareth-21、二甲基聚硅氧烷和环甲基聚硅氧烷混合,并将其加热到大约65℃~75℃。
在一个单独的容器中准备水杨酸相。即在大约65℃~75℃,将水杨酸加到PPG-14丁醚中。
然后,在大约65℃~75℃,将水杨酸相混入油相。在大约65℃~75℃,再将油相的混合物加入水相混合物中,并将其搅拌。将由此得到的混合物冷却到大约40℃~50℃。然后,再将含有次要成份和EDTA二钠的混合物加入到这个乳液中。冷却到室温。
上述组合物的另一制备方法如下:
首先准备水相。即将水加热到大约180°F(82℃),然后加入二硬脂基二甲基氯化铵、甘油、丙二醇、十六烷醇、十八烷醇、Steareth-2、Steareth-21,保持此混合物在大约65℃~75℃。
在一个单独的容器中准备水杨酸相。即在大约65℃-75℃,混合水杨酸、PPG-14丁醚、二甲基聚硅氧烷、和环甲基聚硅氧烷。
然后,在大约65℃~75℃,将水杨酸相混入水相并在大约65℃~75℃,将其搅拌。将由此得到的混合物冷却到大约40℃~50℃。然后,再将含有次要成份和EDTA二钠的混合物加入到这个乳液中。冷却到室温。由于提供了水杨酸,最后得到的组合物用于皮肤上是很有用的,而且可以用于处理皱纹、干性皮肤以及其它与因年龄产生的皮肤问题。
Claims (10)
1.轻松皮肤的护肤组合物,它含有:
(A)重量百分比大约为0.05%~20%,优选大约为0.1%~10%的酸性活性成份,其溶解度参数更优选大约在6~12之间。这些酸性活性成份优选从由水杨酸、乙酰基水杨酸、顺-视黄酸、反-视黄酸、壬二酸、四环素、异丁苯丙酸、甲氧萘丙酸、acetominophen、氢化可的松、间苯二酚、苯氧基乙醇、苯氧基丙醇、苯氧基异丙醇、2,4,4′-三氯-2′-羟基二苯醚、3,4,4′-三氯对称二苯脲、羟甲辛吡酮、2-苯基苯并咪唑-5-磺酸、二羟基丙酮和它们的混合物构成的集合中选择;
(B)大约0.1%~25%的烷氧基醇、烷氧基多元醇和它们的混合物,它们的分子式为:其中,R可以从由醇、多元醇、二醇和它们的混合物组成的集合中选择,要有大约2~10个碳原子的链长;n是大约3~40的一个整数;X可以从由氢、甲基、乙基、丙基或它们的混合物构成的集合中选择;
(C)大约1%~20%的一个酸稳定的,憎水性的结构化试剂,它可以从由饱和的C16到C30的脂肪醇、含有大约1~5摩尔的环氧乙烷的饱和的C16到C30的脂肪醇、饱和的C16到C30的二元醇,饱和的C16到C30的单甘油醚、饱和的C16到C30的羟基脂肪酸和它们的混合物构成的集合中选择,同时要有大约至少45℃的熔点;
(D)大约0.05%~10%的一个酸稳定的亲水性的表面活性剂,可以从由阴离子、阳离子、两性离子、非离子型表面活性剂以及它们的混合物构成的集合中选择。更好的是从阳离子、非离子型表面活性剂以及它们的混合物构成的集合中选择;
(F)大约25%~99.7%的水;其中组合物的PH值大约是3.5或者更低,优选是在2.5~3.5之间,其中组合物的粘度更优选在3,000~200,000cps之间。
2.权利要求1的组合物,其中酸性活性剂要从由水杨酸、水杨酸衍生物、顺-视黄酸、反-视黄酸、壬二酸、异丁苯丙酸、甲氧萘丙酸、2-苯基苯并咪唑-5-磺酸和它们的混合物构成的集合中选择。
3.权利要求1的组合物,其中活性剂是水杨酸,其在组合物中的重量百分比含量大约为组合物重量的0.1%-5%。
4.权利要求1、2或3的组合物,其中阳离子表面活性剂具有分子式:其中,R1是一个含有大约12~30个碳原子的烷基,或者含有大约12~30个碳原子的芳香族的芳基或烷芳基;R2、R3和R4要从氢、含有大约1~22个碳原子的烷基或者含有大约12~22个碳原子的芳香族的芳基或烷芳基独立选择;X是任何相匹配的阴离子;其中阳离子表面活性剂优选从由二-十二烷基二甲基氯化铵、二-硬脂基二甲基氯化铵、二-十四烷基二甲基氯化铵、二-十六烷基二甲基氯化铵以及它们的混合物构成的集合中选择。
5.权利要求1、2或3的组合物,其中非离子表面活性剂要从由具有大约从6到18的HLB值的高HLB非离子表面活性剂、具有大约从1到小于6的HLB值的低HLB非离子表面活性剂以及他们的混合物构成的集合中选择。
6.权利要求5的组合物,其中非离子表面活性剂要从由ceteth-10、steareth-21、椰子烷基聚乙氧基化物(6.5)、癸基聚乙氧基化物(6)、steareth-2以及他们的混合物构成的集合中选择。
7.权利要求1、2或3的组合物,其中成份(C)与成份(D)的比例大约是从20:1~1∶1,优选是大约是从5∶1~1∶1。
8.权利要求1、2或3的组合物,其中烷氧基醇和烷氧基多元醇要从由PPG-14丁醚、PPG-15硬脂醚、PPG-11硬脂醚、PPG-20油醚、PPG-101,4丁二醇、PPG-121,4丁二醇、PPG-101,6己二醇、PPG-12己二醇以及它们的混合物构成的集合中选择,优选是从由PPG-14丁醚、PPG-15硬脂醚、PPG-101,4丁二醇以及它们的混合物构成的集合中选择。
9.权利要求1、2或3的组合物,其中憎水性结构化试剂是从由十八烷醇、十六烷醇、平均含有大约2个环氧乙烷单元的十八烷醇的聚乙烯二醇醚以及它们的混合物构成的集合中选择。
10.权利要求1、2或3的组合物,其中组合物另外还含有大约为组合物重量的1%~5%、优选是大约2%~3.5%的丙二醇。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21241394A | 1994-03-11 | 1994-03-11 | |
US08/212,413 | 1994-03-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1145582A true CN1145582A (zh) | 1997-03-19 |
Family
ID=22790911
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN95192519A Pending CN1145582A (zh) | 1994-03-11 | 1995-03-07 | 含有酸性活性物质的低pH值的水解稳定的化妆品组合物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US5824666A (zh) |
EP (1) | EP0748203A1 (zh) |
JP (1) | JPH09510208A (zh) |
CN (1) | CN1145582A (zh) |
AU (1) | AU702897B2 (zh) |
CA (1) | CA2185231A1 (zh) |
CZ (1) | CZ267396A3 (zh) |
MX (1) | MX9604033A (zh) |
WO (1) | WO1995024179A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102176956A (zh) * | 2008-10-14 | 2011-09-07 | 亚拉国际有限公司 | 通过使用烷氧基化化合物的表面活性剂混合物最小化脲溶液液滴直径的方法 |
WO2020237673A1 (en) * | 2019-05-31 | 2020-12-03 | L'oreal | Composition for cleansing keratin materials |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6248336B1 (en) * | 1995-05-20 | 2001-06-19 | The Procter & Gamble Company | Cosmetic make-up compositions |
UY24246A1 (es) * | 1995-06-06 | 1996-06-14 | Neutrogena Corp | Vehiculos tropicos que contienen acido azelaico solubilizado y estabilizado |
US5948416A (en) * | 1995-06-29 | 1999-09-07 | The Procter & Gamble Company | Stable topical compositions |
US5665364A (en) * | 1995-07-24 | 1997-09-09 | The Procter & Gamble Company | Compositions for topical delivery of active ingredients |
DE19538094C1 (de) * | 1995-10-13 | 1997-02-20 | Kao Corp Gmbh | Verwendung einer wäßrigen Emulsion oder Dispersion als Haarpflegemittel |
EP0896524B1 (en) * | 1996-05-02 | 2003-07-09 | The Procter & Gamble Company | Topical compositions comprising dispersed surfactant complex |
AU726543B2 (en) * | 1996-07-10 | 2000-11-09 | S.C. Johnson & Son, Inc. | Triclosan skin wash with enhanced efficacy |
US5942212A (en) * | 1996-11-19 | 1999-08-24 | E-L Management Corp. | Self tanning composition containing DHA and α hydroxy acids |
FR2756734B1 (fr) * | 1996-12-06 | 1999-01-15 | Oreal | Utilisation de paracetamol comme agent depigmentant |
CN1262615A (zh) * | 1997-06-04 | 2000-08-09 | 普罗克特和甘保尔公司 | 含酸性表面活性剂的、温和漂去型抗微生物液体清洁组合物 |
EP0996421A1 (en) * | 1997-06-04 | 2000-05-03 | The Procter & Gamble Company | Mild, rinse-off antimicrobial liquid cleansing compositions containing salicylic acid |
BR9811706A (pt) * | 1997-06-04 | 2000-07-25 | Procter & Gamble | Composições antimicrobianas brandas sem-remoção |
US6183757B1 (en) | 1997-06-04 | 2001-02-06 | Procter & Gamble Company | Mild, rinse-off antimicrobial cleansing compositions which provide improved immediate germ reduction during washing |
US6190674B1 (en) | 1997-06-04 | 2001-02-20 | Procter & Gamble Company | Liquid antimicrobial cleansing compositions |
US6214363B1 (en) | 1997-11-12 | 2001-04-10 | The Procter & Gamble Company | Liquid antimicrobial cleansing compositions which provide residual benefit versus gram negative bacteria |
US6190675B1 (en) | 1997-06-04 | 2001-02-20 | Procter & Gamble Company | Mild, rinse-off antimicrobial liquid cleansing compositions which provide improved residual benefit versus gram positive bacteria |
US6183763B1 (en) | 1997-06-04 | 2001-02-06 | Procter & Gamble Company | Antimicrobial wipes which provide improved immediate germ reduction |
US6217887B1 (en) | 1997-06-04 | 2001-04-17 | The Procter & Gamble Company | Leave-on antimicrobial compositions which provide improved immediate germ reduction |
WO1998055092A1 (en) | 1997-06-04 | 1998-12-10 | The Procter & Gamble Company | Mild, rinse-off antimicrobial liquid cleansing compositions |
US6284259B1 (en) | 1997-11-12 | 2001-09-04 | The Procter & Gamble Company | Antimicrobial wipes which provide improved residual benefit versus Gram positive bacteria |
US6287577B1 (en) | 1997-11-12 | 2001-09-11 | The Procter & Gamble Company | Leave-on antimicrobial compositions which provide improved residual benefit versus gram positive bacteria |
US6197315B1 (en) | 1997-06-04 | 2001-03-06 | Procter & Gamble Company | Antimicrobial wipes which provide improved residual benefit versus gram negative bacteria |
US6210695B1 (en) | 1997-06-04 | 2001-04-03 | The Procter & Gamble Company | Leave-on antimicrobial compositions |
IT1295290B1 (it) * | 1997-10-07 | 1999-05-04 | Telos S R L | Composizioni cosmetiche a base di acido azelaico |
US20020094341A1 (en) * | 1998-11-03 | 2002-07-18 | Lise W. Jorgensen | Skin moisturizer compositions containing a sebum control agent |
FR2785532B1 (fr) * | 1998-11-06 | 2000-12-15 | Oreal | Procede de maquillage des matieres keratiniques |
US6503488B1 (en) * | 1998-11-17 | 2003-01-07 | Tend Skin International, Inc. | Topical compositions including deodorant compositions |
US6368618B1 (en) | 1999-07-01 | 2002-04-09 | The University Of Georgia Research Foundation, Inc. | Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs |
US20020054895A1 (en) | 1999-07-23 | 2002-05-09 | Alwyn Company, Inc. | Allantoin-containing skin cream |
US6531500B2 (en) | 1999-07-23 | 2003-03-11 | Alwyn Company, Inc. | Methods for treatment of inflammatory diseases |
US6329413B1 (en) | 1999-07-23 | 2001-12-11 | Alwyn Company, Inc. | Allantoin-containing skin cream |
US6864274B2 (en) | 1999-07-23 | 2005-03-08 | Alwyn Company, Inc. | Allantoin-containing skin cream |
US6896897B2 (en) | 1999-07-23 | 2005-05-24 | Alwyn Company, Inc. | Flexible applicator for applying oil-in-water emulsion with improved stability |
US6673826B2 (en) | 1999-07-23 | 2004-01-06 | Alwyn Company, Inc. | Methods for treatment of inflammatory diseases |
US6281236B1 (en) | 1999-07-23 | 2001-08-28 | Alwyn Company, Inc. | Oil-in-water emulsion with improved stability |
US6555573B2 (en) * | 2000-12-21 | 2003-04-29 | The Quigley Corporation | Method and composition for the topical treatment of diabetic neuropathy |
NZ530278A (en) * | 2001-06-01 | 2006-06-30 | Tendskin Company | Topical composition containing a salicylate derivative for veterinary use in treating dermatological disorders |
US6495149B1 (en) | 2001-08-10 | 2002-12-17 | The Procter & Gamble Company | Topical leave-on compositions containing selected pantothenic acid derivatives |
US20030105027A1 (en) * | 2001-11-06 | 2003-06-05 | Rosenbloom Richard A. | Nutritional supplements and methods for prevention, reduction and treatment of radiation injury |
US7435725B2 (en) * | 2001-11-06 | 2008-10-14 | The Quigly Corporation | Oral compositions and methods for prevention, reduction and treatment of radiation injury |
US20030118536A1 (en) * | 2001-11-06 | 2003-06-26 | Rosenbloom Richard A. | Topical compositions and methods for treatment of adverse effects of ionizing radiation |
DE10226201A1 (de) * | 2002-06-12 | 2003-12-24 | Ifac Gmbh & Co Kg Inst Fuer An | Etheralkohole als Lösungsmittel und diese enthaltende Emulsionen und Dispersionen |
JP2004031185A (ja) * | 2002-06-27 | 2004-01-29 | Yazaki Corp | 薄型スイッチ |
US7083813B2 (en) * | 2002-11-06 | 2006-08-01 | The Quigley Corporation | Methods for the treatment of peripheral neural and vascular ailments |
US7179477B2 (en) * | 2003-08-15 | 2007-02-20 | Shyam K Gupta | Cosmetic dermabrasion treatment system |
US20050058673A1 (en) | 2003-09-09 | 2005-03-17 | 3M Innovative Properties Company | Antimicrobial compositions and methods |
US7592300B2 (en) * | 2003-11-24 | 2009-09-22 | The Dial Corporation | Antimicrobial compositions containing an aromatic carboxylic acid and a hydric solvent |
US9028852B2 (en) | 2004-09-07 | 2015-05-12 | 3M Innovative Properties Company | Cationic antiseptic compositions and methods of use |
US8198326B2 (en) * | 2004-09-07 | 2012-06-12 | 3M Innovative Properties Company | Phenolic antiseptic compositions and methods of use |
CA2599653A1 (en) | 2005-03-10 | 2006-09-21 | 3M Innovative Properties Company | Methods of reducing microbial contamination |
CA2599667C (en) | 2005-03-10 | 2014-12-16 | 3M Innovative Properties Company | Antimicrobial compositions comprising esters of hydroxy carboxylic acids |
US20060269499A1 (en) * | 2005-05-25 | 2006-11-30 | Grant Industries, Inc. | Substantive anionic silicone oil emulsion compositions for hair and skin conditioning |
EP1867318A1 (en) * | 2006-06-13 | 2007-12-19 | Wella Aktiengesellschaft | Body Care composition with water-soluble abrasive particles |
US20090018151A1 (en) * | 2007-02-23 | 2009-01-15 | Ezekiel Fink | Topical Treatment of Peripheral diabetic complications |
DE202007011568U1 (de) * | 2007-08-17 | 2009-01-02 | Schwan-Stabilo Cosmetics Gmbh & Co. Kg | Zubereitung mit hautbefeuchtenden Eigenschaften |
EP2376198B1 (en) | 2008-12-22 | 2018-03-28 | Johnson & Johnson Consumer Holdings France | A composition comprising a retinoid and method of treating skin conditions |
US20110081305A1 (en) * | 2009-10-02 | 2011-04-07 | Steven Cochran | Compositions comprising a skin-lightening resorcinol and a skin darkening agent |
US20140135372A1 (en) | 2010-02-02 | 2014-05-15 | Elliott Farber | Compositions and methods of treatment of inflammatory skin conditions using allantoin |
US10111956B2 (en) | 2013-06-03 | 2018-10-30 | Tolmar, Inc. | Corticosteroid compositions |
KR101868692B1 (ko) * | 2016-09-20 | 2018-06-18 | 가천대학교 산학협력단 | BDD(biphenyl dimethyl dicarboxylate)를 유효성분으로 함유하는 피부 미백, 피부 주름 개선 및 피부노화 예방 및 치료용 약학적 조성물 |
US11795192B2 (en) | 2017-03-10 | 2023-10-24 | Lakewood Amedex, Inc. | Antimicrobial compounds, compositions, and uses thereof |
KR20230031370A (ko) * | 2017-06-12 | 2023-03-07 | 레이크우드 아메덱스, 인크. | 비스포스포신 겔 제제 및 이의 용도 |
CN110785161B (zh) | 2017-06-23 | 2023-06-20 | 宝洁公司 | 用于改善皮肤外观的组合物和方法 |
CA3102288A1 (en) | 2018-07-03 | 2020-01-09 | The Procter & Gamble Company | Method of treating a skin condition |
JP2022503733A (ja) | 2018-10-17 | 2022-01-12 | レイクウッド アメディックス、インコーポレイテッド | 口腔粘膜炎を治療するための方法および組成物 |
WO2021247496A1 (en) | 2020-06-01 | 2021-12-09 | The Procter & Gamble Company | Method of improving penetration of a vitamin b3 compound into skin |
US10959933B1 (en) | 2020-06-01 | 2021-03-30 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
WO2024113155A1 (en) * | 2022-11-29 | 2024-06-06 | L'oreal | Cosmetic composition for caring keratin material |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3355387A (en) * | 1963-12-19 | 1967-11-28 | Sterling Drug Inc | Cleansing composition |
US4822604A (en) * | 1985-05-20 | 1989-04-18 | S. C. Johnson & Son, Inc. | Local treatment of dandruff, seborrheic dermatitis, and psoriasis |
US4732930A (en) * | 1985-05-20 | 1988-03-22 | Massachusetts Institute Of Technology | Reversible, discontinuous volume changes of ionized isopropylacrylamide cells |
EP0347145A3 (en) * | 1988-06-14 | 1990-10-24 | University Of Utah Research Foundation | Heterogeneous interpenetrating polymer networks for the controlled release of drugs |
US5262407A (en) * | 1988-12-16 | 1993-11-16 | L'oreal | Use of salicylic derivatives for the treatment of skin aging |
JPH0699285B2 (ja) * | 1989-07-07 | 1994-12-07 | 花王株式会社 | 毛髪化粧料 |
US5073372A (en) * | 1990-11-30 | 1991-12-17 | Richardson-Vicks, Inc. | Leave-on facial emulsion compositions |
WO1992013566A1 (en) * | 1991-01-31 | 1992-08-20 | Massachusetts Institute Of Technology | Interpenetrating-polymer network phase-transition gels |
US5229104A (en) * | 1991-04-29 | 1993-07-20 | Richardson-Vicks Inc. | Artificial tanning compositions containing positively charged paucilamellar vesicles |
CA2141192C (en) * | 1992-07-28 | 1999-02-02 | Roberta C. Bloom | Pharmaceutical composition for topical use containing a crosslinked cationic polymer and an alkoxylated ether |
EP0714283B1 (en) * | 1993-07-03 | 1999-05-12 | The Procter & Gamble Company | Personal cleansing compositions |
US5484597A (en) * | 1993-07-30 | 1996-01-16 | Chesebrough-Pond's Usa Co. | Clear hydroalcholic cosmetic microemulsions |
US5482710A (en) * | 1993-07-30 | 1996-01-09 | Chesebrough-Pond'usa Co., Division Of Conopco, Inc. | Cosmetic composition for treatment of pimples and redness |
US5618522A (en) * | 1995-01-20 | 1997-04-08 | The Procter & Gamble Company | Emulsion compositions |
US5665364A (en) * | 1995-07-24 | 1997-09-09 | The Procter & Gamble Company | Compositions for topical delivery of active ingredients |
US5652522A (en) * | 1995-09-21 | 1997-07-29 | Hughes Electronics | Dielectric-loaded surface-condition sensor and method |
-
1995
- 1995-03-07 CZ CZ962673A patent/CZ267396A3/cs unknown
- 1995-03-07 WO PCT/US1995/002840 patent/WO1995024179A1/en not_active Application Discontinuation
- 1995-03-07 MX MX9604033A patent/MX9604033A/es unknown
- 1995-03-07 CA CA002185231A patent/CA2185231A1/en not_active Abandoned
- 1995-03-07 JP JP7523594A patent/JPH09510208A/ja active Pending
- 1995-03-07 AU AU19825/95A patent/AU702897B2/en not_active Ceased
- 1995-03-07 EP EP95912775A patent/EP0748203A1/en not_active Withdrawn
- 1995-03-07 CN CN95192519A patent/CN1145582A/zh active Pending
- 1995-12-21 US US08/576,264 patent/US5824666A/en not_active Expired - Fee Related
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102176956A (zh) * | 2008-10-14 | 2011-09-07 | 亚拉国际有限公司 | 通过使用烷氧基化化合物的表面活性剂混合物最小化脲溶液液滴直径的方法 |
CN102176956B (zh) * | 2008-10-14 | 2013-11-06 | 亚拉国际有限公司 | 通过使用烷氧基化化合物的表面活性剂混合物最小化脲溶液液滴直径的方法 |
US9050560B2 (en) | 2008-10-14 | 2015-06-09 | Yara International Asa | Method for minimizing the diameter of a urea solution, urea solution and use of a surfactant in urea solution |
WO2020237673A1 (en) * | 2019-05-31 | 2020-12-03 | L'oreal | Composition for cleansing keratin materials |
CN113873988A (zh) * | 2019-05-31 | 2021-12-31 | 莱雅公司 | 用于清洁角蛋白材料的组合物 |
CN113873988B (zh) * | 2019-05-31 | 2023-10-03 | 莱雅公司 | 用于清洁角蛋白材料的组合物 |
Also Published As
Publication number | Publication date |
---|---|
AU1982595A (en) | 1995-09-25 |
AU702897B2 (en) | 1999-03-11 |
CA2185231A1 (en) | 1995-09-14 |
EP0748203A1 (en) | 1996-12-18 |
JPH09510208A (ja) | 1997-10-14 |
MX9604033A (es) | 1997-09-30 |
CZ267396A3 (en) | 1997-03-12 |
US5824666A (en) | 1998-10-20 |
WO1995024179A1 (en) | 1995-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1145582A (zh) | 含有酸性活性物质的低pH值的水解稳定的化妆品组合物 | |
US5989536A (en) | Personal cleansing compositions containing alkoxylated ether and cationic ammonium salt for deposition of active agent upon the skin | |
JP3567990B2 (ja) | 架橋陽イオン重合体とアルコキシ化エーテルとを含有する局所用途用医薬組成物 | |
EP0714283B1 (en) | Personal cleansing compositions | |
CN1051919C (zh) | 同时治疗皮肤表层和深层用的除色素组合物及其应用 | |
CN1090941C (zh) | 含过氧化苯甲酰和可降低对皮肤刺激性的化合物的皮肤用组合物 | |
RU2245706C2 (ru) | Продукт в виде косметических салфеток | |
JPH11508560A (ja) | 安定な局所組成物 | |
CN1195980A (zh) | 用于局部输送活性成分的组合物 | |
US6607735B2 (en) | Method for reducing the appearance of dark circles under the eyes | |
JPH09500890A (ja) | 化粧品用ヒドロアルコール性マイクロエマルジョン | |
CN1070699C (zh) | 含n-乙酰-l-半胱氨酸的局部使用的组合物 | |
JP2002539230A (ja) | 濡れナプキン製品 | |
CN1993102A (zh) | 包含脒和烷烃多元醇的组合物 | |
CN1787805A (zh) | 透明的水包油乳剂 | |
US8524258B2 (en) | Structured lotions | |
CN1300588A (zh) | 含氨基酚衍生物的化妆品组合物 | |
CN1063038A (zh) | 存留于面部的乳液组合物 | |
JPH0995411A (ja) | 皮膚外用剤 | |
JP3513861B2 (ja) | 皮膚外用剤 | |
MXPA96004033A (en) | Low ph, hydrolically stable cosmetic compositions containing aci assets | |
JPH09169666A (ja) | 抗炎症皮膚外用剤 | |
MXPA94005931A (en) | Compositions of oil emulsion in water for personal cleaning | |
JPH10245330A (ja) | 皮膚外用剤 | |
FR2949968A1 (fr) | Composition injectable comprenant une dispersion vesiculaire comprenant des ceramides et de l'acide hyaluronique, utilisation et procede |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C01 | Deemed withdrawal of patent application (patent law 1993) | ||
WD01 | Invention patent application deemed withdrawn after publication |